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SUMMARY
The aims of this study were to identify latently infected 
cats; to determine the prevalence of latent infections in 
FeLV-positive multicat households and the duration of such 
infections; to investigate the clinical and epidemiological 
significance of these infections, in a closed multicat household; 
and to investigate the mechanisms involved in the control of 
latency.
Chapter 1 is a General Introduction which outlines the 
general biology and epidemiology of FeLV and describes in detail 
the previous work which led to the present study.
Chapter 2 describes the General Materials and Methods 
employed during the course of the study. Specialised methods are 
detailed at the beginning of each subsequent Chapter.
The next chapter, Chapter 3, describes the techniques 
developed to detect latent FeLV infection in cats. Latent virus
was found in the bone marrow of cats which had virus neutralising
antibodies (VNAs) and were therefore believed to have recovered 
from infection. Those methods which have been used in previous 
studies to detect these infections are then described, followed by 
an account of the methods used here. The latter involve the 
culture of aspirated bone marrow cells followed by the detection 
of reactivated virus by either virus isolation from cell culture
fluids or by immunofluorescence (IF) techniques carried out on the
cultured cells. IF was the more efficient method as it could 
detect viral antigen within one week of culture. These methods 
could not detect any virus or viral antigen prior to the culture 
of the bone marrow cells. Finally in this Chapter an attempt was 
made to quantitate the proportion of latently infected cells by 
the use of infectious centre assays. It was found that the 
proportion of these cells was low and ranged from 3 to 400 per 
million.
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The prevalence and duration of latent infections in a 
closed, FeLV-exposed multicat household are discussed in Chapter
4. Nineteen SPF cats were housed together with 4 cats excreting 
FeLV. It was found that the proportion of ostensibly recovered 
cats (i.e. cats which had VNAs and were not viraemic) with latent 
infections was initially high, being approximately 50% 36 weeks 
after initial exposure to the viraemic cats. This proportion 
gradually decreased with time, the greatest decline occurring 
between 36 and 64 weeks after exposure. After 3 years only one of 
these cats still had a latent infection. Most latent infections 
are therefore short-lived with approximately 10% being long-term. 
Those cats which appeared to eliminate the latent virus were then 
believed to have truly recovered from infection. Possible reasons 
for the termination of latent infection are discussed.
Chapter 5 investigates the clinical and epidemiological 
significance of latency. Twenty-six latently infected cats were 
studied for periods of up to 4 years, and none developed any of 
the common FeLV-associated diseases. Latently infected cats 
therefore appeared to be no more at risk of developing these 
diseases than unexposed cats. The second part of this Chapter 
considers the possibility of horizontal or congenital transmission 
of infection from latently infected cats. After one year of 
exposure to 8 such cats, 8 susceptible FeLV-niaive cats showed no 
evidence of having been infected with the virus. Similarly the 
kittens of 7 of 8 latently infected queens had no evidence of 
congenital or post-natal infection from, their mothers. However, 
the kittens of 4 consecutive litters of the eighth queen became 
persistently viraemic at 6-8 weeks of age and the source of the 
virus was found to be her milk. This queen herself subsequently 
became viraemic. The epidemiological importance of such cats for 
the control and eradication of FeLV from multicat households is 
discussed.
Attempts to determine the mechanisms which control latent 
infections are detailed in Chapter 6. It was believed that VNAs 
might be important since all latently infected cats possess these
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antibodies and the culture of their bone marrow in the absence of 
VNAs resulted in virus reactivation. By contrast, it was found 
that when latently infected bone marrow cells were cultured in the 
continuous presence of cat sera containing VNA, virus reactivation 
was inhibited. Further it was found by the use of mouse
monoclonal antibodies to FeLV proteins that the epitope involved 
in reactivation inhibition (RI) was that on the gp70 which is 
involved in neutralisation. The VNA and RI titres of the 
inhibiting antibodies were closely correlated (r = 0.89).
Attempts were then made to elucidate the means by which 
neutralising antibody maintained latent infections. It was clear 
that the antibody was neither cytolytic nor cytotoxic since
inhibition was reversible upon the removal of antibody, but it 
appeared from those experiments involving the mixing of bone 
marrow cells from a viraemic and an uninfected cat that the
antibody prevented the spread of virus from the cells of the
viraemic cat to those of the uninfected cat. Other possibilities 
of the antibody preventing the transcription of viral antigen or 
preventing the assembly or budding of virus at the cell membrane 
are discussed.
The General Discussion (Chapter 7) assesses the extent to 
which the aims of this study were achieved. Particular attention 
is paid to the mechanisms of control of other persistent viral 
infections including the paramyxoviruses, herpesviruses and other 
retroviruses. Methods by which further investigation into the 
controlling mechanisms of latent FeLV infection might be carried 
out are suggested.
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CHAPTER 1 
GENERAL INTRODUCTION
1. Feline leukaemia virus
a) Discovery of the virus
Feline leukaemia was first reported to be an infectious 
disease by Jarrett et al. (1964a) who inoculated a homogenate of 
the tumour from a field case of thymic lymphosarcoma into 4 
newborn kittens by subcutaneous injection and found that they all 
developed lymphosarcoma. Electron microscopy carried out on the 
tissues of one of these kittens demonstrated the presence of 
virus-like particles in intracellular vescicles (Jarrett et al. , 
1964b) which resembled the viruses known to cause leukaemia in mice 
and chickens.
Rickard et al. (1967) obtained a similar result and later 
reported that a virus-induced lymphocytic leukaemia was serially 
transmissible and 56 of 68 kittens which were inoculated with 
cell-free extracts developed lymphosarcoma (Rickard et al., 1969). 
Kawakami et al. (1967) demonstrated virus particles in the plasma 
of cats with leukaemia. These authors also showed that the disease 
was transmissible when kittens were inoculated intraperitoneally 
with material from a leukaemic cat.
The virus demonstrated in these experiments, feline leukaemia 
virus (FeLV), was recognised as belonging to the family of viruses 
now known as retroviruses (Fenner, 1975-76).
b) Structure of FeLV
FeLV is a typical retrovirus. The RNA genome consists of 3 
genes, gag, pol and env, arranged from the 5* to 3 ! end, which code 
for the structural proteins and the enzyme, reverse transcriptase 
(RT). The gag gene (group-specific antigen gene) codes for the 
polyprotein precursors of the internal core proteins with molecular 
weights of 27,000 (p27), 15,000 (pl5), 12,000 (pl2) and 10,000 
(plO) (Graves and Velicer, 1974). These are similar in all FeLV 
isolates. The pol (polymerase) gene codes for the RT and the env
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(envelope) gene codes for the polyprotein precursor of the 
envelope proteins. This precursor is cleaved to give a 
glycoprotein of 70,000 daltons (gp70) and an unglycosylated protein 
of 15,000 daltons (pl5(E)). Variations in the env gene sequences 
give subgroup specificity to each isolate (see Section Id).
Flanking the gag, pol and env genes at the 5' and 3' ends of 
the genome are regions containing sequences which regulate and 
enhance viral transcription.
In the virion the viral RNA is surrounded by a protective 
protein core consisting of p27, pl5 and plO. These proteins are 
hexagonally arranged and also surround the RT (Scolnik et al. , 
1970). Outside this core is an inner protein coat consisting of 
pl2. The outermost structure is the viral envelope which is a 
phospholipid membrane into which is inserted the gp70 and pl5(E). 
The gp70 forms spikes on the exterior of the virus particle and is 
anchored into the membrane by the hydrophobic pl5(E) (Bolognesi et 
al., 1978).
°) Replication of FeLV
After FeLV has adsorbed to and penetrated its host cell, the 
virus loses its envelope in order to release the RNA. A single 
stranded DNA copy of the RNA is then made using the viral RT. This 
single stranded DNA acts as a template for a double stranded DNA 
provirus. The provirus circularises and integrates into the host 
cell chromosome. Thus, the provirus becomes part of the cellular 
genome. This process can only occur in cells which are undergoing 
DNA synthesis (Temin, 1971). It should be noted that several 
copies of endogenous FeLV-like sequences occur in the cellular DNA 
of the domestic cat (Sarma et al., 1974; Niman et al., 1977; Okabe 
et al., 1976; Koshy et al., 1980; Soe e t a l . , 1983).
Two species of mRNA are transcribed from proviral DNA: 
firstly, the whole genome (gag-pol-env) from which the gag and pol 
proteins are translated; and secondly, env which is transcribed
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independently. A precursor, Pr65 Sa§, is made from which the gag 
proteins are produced. The env precursor Pr80 env is processed to 
gp70 and p!5(E) (Neil and Onions, 1985).
The components of the virus envelope migrate to the cell 
surface and are inserted into the plasma membrane (Bolognesi e^t 
al., 1978) to form an evagination called the viral bud (Schafer and 
Bolognesi, 1977; Bolognesi et al., 1978). The gag polyprotein
precursor is then transported to this site. One end of this 
molecule is linked to the viral envelope and the other to the viral 
RNA (Bolognesi et al., 1978). This precursor is then cleaved to 
form the individual core proteins (pl5, pl2, p27 and plO) which 
align to form the internal structures of the virus. The env 
precursor is glycosylated and cleaved to produce gp70 and pl5(E) 
(Bolognesi et al., 1978). The pl5(E) is then further processed to 
give pl2(E) (Neil et al., 1980a). When maturation is complete 
infectious virus particles are budded off without damaging the host 
cell.
d) Subgroups of FeLV
FeLV occurs in 3 distinct subgroups which are defined by 
interference; A (FeLV-A), B (FeLV-B) and C (FeLV-C) (Sarma and Log, 
1971; 1973). The occurrence of the different subgroups in the
field has been described in detail by Jarrett (1980). It is
believed that the structure of the envelope glycoprotein, gp70, 
determines subgroup specificity.
The subgroup of any particular strain of FeLV is important in 
determining its host range in vitro. As described in Section le,
FeLV-A is only capable of infecting feline cells, i.e. is
ecotropic, whereas FeLV-B and FeLV-C also infect human cells, i.e.
are xenotropic (Jarrett et al., 1973c).
Jarrett (1980) found that all strains of FeLV were anti- 
genically closely related and shared group specific antigens.
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Although Sarnia and Log (1973) reported the occurrence of distinct 
subgroups by virus neutralisation, Russell and Jarrett (1978a) 
found that by using this technique there was extensive 
cross-reactivity between subgroups, since antibody which 
neutralised FeLV-A often neutralised FeLV-C, but to a lesser 
degree. Russell and Jarrett (1978a) also found that FeLV-A 
isolates were monotypic but that there was antigenic variation 
amongst FeLV-B and FeLV-C isolates.
In the field FeLV-A is by far the most common subgroup and is 
present in all isolates. FeLV-B and FeLV-C occur, but invariably 
FeLV-A is also present (Sarma and Log, 1971; 1973; Jarrett et al., 
1978a). It appears that FeLV-B and FeLV-C viruses are recombinants 
between FeLV-A and cellular FeLV-related DNA sequences (Russell and 
Jarrett, 1978a; Stewart et al., 1986). Jarrett et al. (1978a) 
found that in healthy FeLV-positive cats, 65% had FeLV-A, 33% had 
FeLV-AB, and FeLV-C was only isolated from diseased cats.
The efficacy of replication of FeLV in the cat is related both 
to subgroup of the virus and age of the cat. For example, 
experimentally, FeLV-A will infect 100% of cats younger than 16 
weeks of age, whereas FeLV-B will infect only 20% of newborn 
kittens and will not infect older kittens (Jarrett, 1980). Jarrett 
et al. (1978b) and Jarrett and Russell (1978) reported that FeLV-A 
and FeLV-B behaved differently in terms of transmission between 
cats and growth in the cat. They found that FeLV-A was readily 
transmitted between cats, but that FeLV-B could only be transmitted 
as a phenotypic mixture with subgroup A, i.e. FeLV-AB. These 
authors also found that FeLV-B had restricted growth in cats and 
that FeLV-A enhanced the growth of FeLV-B in vivo. FeLV-C appears 
to be intermediate in its behaviour in that it will infect 100% of 
newborn kittens (Onions et al., 1982), 50% of 2 week old kittens 
but will not infect 8 week old kittens (Jarrett, 1980). Jarrett et 
al. (1984) found that simultaneous infection with FeLV-A enhanced 
the growth of FeLV-C in the cat and overcame the age related 
resistance to FeLV-C.
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There is some evidence that FeLVs of different subgroups are 
involved in specific types of disease as discussed in Section 2.
e) Growth of FeLV in cell culture
FeLV was first reported to grow in culture by Jarrett et al. 
(1968) who infected two cell lines with cell-free homogenates from 
field cases of lymphosarcoma. One of these lines was derived from 
combined spleen, thymus, liver, kidney and heart of newborn kittens 
(NK cells) and the other was established from the lungs of feline 
embryos (FL cells). Both of these cell lines consisted 
predominantly of fibroblasts and grew as cell monolayers. It was 
found that FeLV was capable of replicating continuously in 
homologous cell cultures without causing a cytopathic effect.
Theilen et al. (1969) succeeded in maintaining suspension cell 
cultures which continuously produced virus. These cells (FL74) 
were transformed lymphocytes derived from a renal lymphosarcoma.
Jarrett et al. (1973c) reported that although all FeLV 
isolates, irrespective of subgroup, grew in feline embryo (FE) 
cells, the subgroup of each isolate was important in determining 
its ability to grow in the cells of other species. They found that 
FeLV-B and FeLV-C grew in human embryonic lung (HEL) cells whereas 
FeLV-A did not (Jarrett et al., 1969). However isolates which 
contained both subgroups A and B in a phenotypic mixture were 
capable of infecting these cells (Jarrett et al., 1973c). FeLV-A, 
therefore, has a restricted host range.
f) Detection of FeLV in cell culture
The presence of FeLV in cell culture can be demonstrated in a 
number of ways including electron microscopy (Jarrett et al. , 
1968), interference (Fischinger and O'Connor, 1969), immuno­
fluorescence (Hardy et al., 1973b), complement fixation (Sarma et 
al., 1971), radioactive labelling of particles having character­
istic bouyant density (Jarrett et al. , 1971) and virus isolation 
from culture fluids (Fischinger et al., 1974). The most common 
techniques currently in use are virus isolation and 
immunofluorescence.
2. Diseases associated with FeLV infection
FeLV is widespread in cat populations and excluding trauma is 
probably the most common single cause of death in adult cats 
(Jarrett, 1984; 1985a). A large number of diseases are associated 
with the virus which are listed in Table 1.1 and have been 
described in detail (Hardy, 1980a; Jarrett, 1984).
The diseases can be divided into two categories. Firstly, 
there are proliferative or malignant diseases. These include 
lymphosarcomas (alimentary, multicentric and thymic) and leukaemias 
(lymphatic, myeloid and erythroid). Of these, lymphosarcomas are 
much more commonly diagnosed. However FeLV is not isolated from 
all cats with lymphosarcoma (Laird et al., 1968; Hardy et al. , 
1980). For example, while 90% of cats with thymic lymphosarcoma 
and 60% of cats with multicentric lymphosarcoma are viraemic only 
30% of cats with alimentary lymphosarcoma are viraemic. There is 
some evidence that cats with lymphosarcoma which are not viraemic 
at the time of diagnosis have had previous contact with FeLV 
(Russell and Jarrett, 1978b; Hardy et al., 1980). Cats with thymic 
lymphosarcoma are generally much younger than cats with other kinds 
of lymphosarcoma, with an average age of 2.5 years (Hardy, 1980a).
Secondly, there are degenerative diseases which include 
anaemias such as erythroid hypoplasia and haemolytic anaemia, bone 
marrow aplasia, immunosuppression and reproductive failure such as 
early foetal death or abortion.
Immunosuppression can occur in both kittens and adult cats. 
Kittens born to viraemic queens may develop thymic atrophy with 
T-lymphocyte depletion leading to a defective cell mediated immune 
response (Anderson et al., 1971; Hardy, 1980a). In adult cats 
immunosuppression is the most common cause of death associated with 
FeLV. Such cats are susceptible to a number of intercurrent 
diseases such as feline infectious peritonitis, feline infectious 
anaemia, chronic upper respiratory infections, enteric infections 
and septicaemia.
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TABLE 1.1
Diseases associated with FeLV infection
Malignant haemopoietic diseases.
Lymphoid tumours : thymic lymphosarcoma
multicentric lymphosarcoma 
alimentary lymphosarcoma
Leukaemias : myeloid leukaemia
erythroid leukaemia 
lymphatic leukaemia
Non-malignant haemopoietic diseases.
Anaemia : haemolytic anaemia
erythroid hypoplasia
Immunosuppression : thymic atrophy
Marrow aplasia
Myelofibrosis and osteosclerosis
Non-haemopoietic diseases.
Reproductive failure : foetal resorption
abortion
FeLV-associated anaemia can occur as a primary result of 
virus infection, as in erythroid hypoplasia, or secondary to other 
primary effects of the virus, e.g. lymphosarcoma (Mackey et al. , 
1975; Hardy, 1980a). Other conditions which often occur secondary 
to erythroid hypoplasia are myelofibrosis and osteosclerosis 
(Hoover and Kociba, 1974; Onions et al., 1982).
There is some evidence that certain diseases are attributable 
to particular subgroups of the virus. In cats with lymphosarcoma, 
Jarrett et al. (1978a) found that 42% had FeLV-A and 58% had 
FeLV-AB. FeLV-C, however, is often associated with erythroid 
hypoplasia (Jarrett, 1980; Onions et al., 1982; Jarrett et al. , 
1984).
The pathogenesis of FeLV infection will be described in 
Section 5.
3. Source of FeLV
Cats which are persistently viraemic represent the major 
source of infection for susceptible cats. Hardy et al. (1973a) 
postulated that the saliva, blood and urine of such cats were 
possible sources of infectious virus and that saliva was the most 
likely of these. Francis et al. (1977) confirmed that virus was 
present in bodily secretions and that it was excreted continuously 
from the mouth of viraemic cats. Saliva containing virus is 
therefore the most important source of infection. As described in 
Chapter 5, FeLV can be transmitted in milk. The possibility of 
blood-sucking parasites such as fleas acting as vectors of the 
virus was considered by Hardy et al. (1973a) but this has never 
been proven to be important.
4* Transmission of FeLV
Transmission of the infection occurs in 2 main ways. 
Congenital transmission occurs when virus crosses the placenta to 
infect developing embryos. As mentioned in Section 2, reproductive
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failure may follow congenital transmission. Any kittens born to a 
persistently viraemic queen, however, are themselves persistently 
viraemic (Jarrett and Russell, 1978) and generally succumb to one 
of the FeLV-associated diseases within 2 years.
The other major mode of transmission is by horizontal transfer 
of virus-containing saliva from persistently viraemic cats to 
susceptible cats (Hardy et al., 1973a). Jarrett et al (1973b) 
found that horizontal transmission of infection occurred within one 
month of mixing viraemic cats with susceptible cats. Although 
aerosolisation of oronasal secretions may transmit virus, it is 
likely that direct intimate contact between cats such as licking is 
necessary in order to transfer sufficiently high doses of virus to 
result in infection (Hoover et al., 1977a).
Indirect transmission, such as spread of virus by contaminated 
feed bowls or attendants’ hands, is thought to be unimportant.
5. In vivo spread of FeLV
Oronasal administration of FeLV has been used experimentally 
to simulate natural infection (Hoover et al., 1972). Rojko et al. 
(1979a) used this method of infection to investigate the sites of 
initial virus replication and the spread of virus within the cat. 
Virus was detected in tissues by immunofluorescence.
Infection begins when virus enters and grows in the cells of 
the oropharynx and upper respiratory tract. Within 3 days virus 
can be detected in reticular cells and germinal centres of local 
lymph nodes and a small proportion of circulating lymphocytes and 
monocytes also contain virus. Dissemination of virus-infected 
lymphocytes then occurs and by 7-14 days these can be found in the 
bone marrow, in blood and lymphatic vessels in lymph nodes, in the 
thymus and in Peyer's patches. Viral antigen is concentrated in 
actively dividing cells in these tissues.
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The virus then spreads to non-lymphoid haemopoietic tissues so 
that by 14-21 days viral antigen is detected in an increasing 
proportion of bone marrow cells, particularly myelomonocytic 
cells. The amount of antigen present in granulocytes increases as 
the cells mature. Circulating neutrophils and platelets by this 
time contain considerable quantities of viral antigen. The release 
of free virus particles into the blood coincides with the 
appearance of antigen-containing neutrophils and platelets and the 
growth of virus in the marrow (Hoover et al., 1977b).
Finally, from 28 to 56 days after infection the virus is 
spread to non-haemopoietic tissues throughout the body, 
particularly the epithelial cells of the oropharynx, salivary 
glands, bladder, intestine and pancreas. Infectious virus is then 
released from these organs.
6. Outcomes of infection with FeLV
Although the cycle of infection with FeLV as described by 
Rojko et al. (1979a) can take up to 56 days to reach completion, 
the outcome of the infection is often determined earlier. Russell 
and Jarrett (1978b) and Rojko et ai. (1979a) found that when cats 
were experimentally inoculated with virus the outcome of the 
infection was determined within 28 days. However when cats which 
were susceptible to the virus were mixed with cats which were 
excreting virus and thus developed an infection, it could be as 
long as 10 weeks after mixing before the outcome was resolved 
(Russell and Jarrett, 1978b). The latter situation would mimic the 
conditions in the field where the interval between mixing and the 
development of sufficient socialising in order to transmit virus 
may be prolonged.
There are three possible outcomes of infection: productive
persistent infection, recovery or latency. Productive persistence 
and recovery will be discussed in this Section and latency will be 
discussed in Section 10.
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a) Productive persistent infection
This type of infection is characterised by viraemia when free 
infectious virus is present in the blood. Approximately half of 
the cats which were experimentally inoculated with virus when 16 
weeks old developed persistent viraemia while the other half had a 
transient viraemia (Jarrett et al., 1982).
In persistently viraemic cats the virus has completed all of 
the stages of pathogenesis and is excreted in the saliva, urine and 
faeces. Such cats fail to mount an effective anti-viral immune 
response and are susceptible to the diseases described above. The 
longterm prognosis for persistently viraemic cats is very poor. 
Francis and Essex (1980) found that the average time from first 
diagnosis of viraemia until death was 22.6 months and McClelland et 
al. (1980) found in their extensive study that 83% of persistently 
viraemic pet cats were dead within 3.5 years of exposure compared 
to only 17% of uninfected cats and 16% of exposed, non-viraemic 
cats.
The duration of a transient viraemia can range from a few days 
to several weeks (Jarrett et al., 1982). Rojko et al. (1979a) 
suggested that the infection in these cats is suppressed before the 
virus begins to replicate in the marrow. However, these results 
are contrary to those of Jarrett et al. (1982) who found that even 
if a cat was only viraemic for a few days, infectious virus was 
isolated from its saliva, suggesting that the virus had become 
disseminated to the tissues before becoming suppressed.
Transiently viraemic cats suppress their infection and appear 
to recover by mounting an immune response as described below.
i) Detection of viraemia
Viraemia can be detected in several ways including 
immunofluorescence on blood smears to detect group specific (p27) 
antigen in the cytoplasm of platelets and neutrophils (Hardy et
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al., 1973b); detection of p27 in blood by enzyme-linked immuno- 
sorbant assay (ELISA) (Lutz et al., 1983), and virus isolation from 
blood (de Noronha et al. , 1977; Jarrett et al. , 1982) and saliva 
(Francis et al., 1977; Jarrett et al., 1982). Jarrett et al.
(1982) reported an unusual cat which had detectable virus in the 
saliva but not in the blood. This may have been due to a sampling 
error since virus had been isolated from its blood as well as from 
saliva on previous samplings and was again isolated subsequently. 
It is possible, however, that virus is occasionally present in 
saliva but not in blood since a similar case has recently been 
observed (H. Lutz and 0. Jarrett; personal communication).
The methods used in this study to detect viraemia were ELISA 
(Leukassay F; C-Vet) and virus isolation from plasma. It should be 
noted that approximately 10% of cats which are positive on ELISA 
for the presence of p27 antigen in blood (antigenaemic) are not 
viraemic as determined by virus isolation (Jarrett, 1985b). The 
results obtained by ELISA were therefore always confirmed by virus 
isolation in this study.
b) Recovery
Cats which recover from infection with FeLV may or may not 
develop a transient antigenaemia and/or viraemia. Recovery is 
associated with the development of an immune response to FeLV.
Two types of antibodies are found in recovered cats. Firstly, 
virus neutralising antibodies (VNAs) may be present which 
inactivate virus in vitro and, by fixing complement, kill cells 
which are expressing virus (Grant et al. , 1983). These antibodies 
are presumed to have a similar effect in vivo and are often 
detected in cats which have eliminated a transient viraemia 
(Jarrett et al., 1973b; 1977; Pedersen et al., 1977). Even small 
amounts of VNAs protect kittens from viraemia when they are 
challenged with large doses of virus (Jarrett et al., 1977).
The second antibody which is produced is against a cell 
membrane antigen, feline oncornavirus-associated cell membrane
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antigen (FOCMA). FOCMA was originally defined as an antigen on the 
surface of the FL74 line of feline lymphosarcoma cells (Theilen et 
al. , 1969) which reacted with sera from cats recovered from feline 
sarcoma virus infection (Essex et al., 1971b) or exposure to FeLV 
(Riggs, 1971). This antigen was originally believed by some to be 
a virus-coded transformation-specific antigen (Hardy et al., 1977) 
although now there is evidence that there may be a relationship 
between FOCMA and an envelope antigen of FeLV-C (Vedbrat et al. , 
1983). Anti-FOCMA antibodies are very common in cat sera (Jarrett 
et al., 1973a; Rogerson et al., 1975). They do not protect the cat 
against persistent infection since persistently viraemic cats often 
have low levels of these antibodies. However, Essex et al. (1971a) 
suggested that anti-FOCMA antibodies protect cats against 
progressive tumour development.
Anti-FOCMA antibodies are very common amongst free-range urban 
cats. Rogerson et al. (1975) found that 40% of urban cats had 
these antibodies compared to 6% of rural cats. This was confirmed 
by Russell and Jarrett (1978b) who found that 50% of urban cats had 
anti-FOCMA antibodies in their sera whereas only 4% had VNAs. 
Whatever the specificity and function of anti-FOCMA antibodies it 
is generally regarded that their presence in the serum of a cat is 
a sensitive indicator of exposure to the virus.
There is also some evidence for a cellular immune response 
being involved in recovery from FeLV infection (Rojko et al. , 
1982). These authors found that peripheral blood mononuclear 
leucocytes from latently infected cats were cytotoxic for 
autochthonous bone marrow cells which had been cultured and had 
reactivated infectious virus, but were not cytotoxic for freshly 
obtained marrow cells which did not express virus (see Section 10). 
There is no further information available on cellular immunity to 
FeLV infections although it is considered likely that it is 
important in eliminating FeLV-infected cells.
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7. Factors which influence the outcome of FeLV infection .
There are a number of factors which influence the outcome of 
infection with FeLV. Probably the most important is the age at 
which the cat is first exposed to the virus. Hoover et al. (1976) 
found that the susceptibility of cats to the infection decreased 
with age. Upon experimental inoculation of FeLV the percentage of 
cats which developed persistent viraemia was 100% of newborn 
kittens, 85% of kittens between 2 weeks and 2 months of age and 
only 15% of cats aged between 4 months and 1 year. The remaining 
cats became immune. Similar results were obtained by Rojko et al 
(1979a) who suggested that young cats may be more at risk to 
infection because they have a larger population of potential target 
cells in their bone marrow than adults.
The proportion of cats which becomes viraemic following FeLV 
infection may be a function of the dose of virus and the frequency 
of exposure to the virus (see Section 8 below). Large doses and 
frequent exposure, especially for young kittens, increase the 
probability of persistent viraemia (Hoover et al., 1976).
A defective immune system can also play a role in determining 
the outcome of infection. Cats which have intercurrent disease and 
may therefore be immunosuppressed, or cats which are iatrogenically 
immunosuppressed by prolonged or high doses of corticosteroids or 
other immunosuppressive drugs, have an increased risk of becoming 
persistently viraemic. Indeed, Rojko et al. (1979b) found that the 
natural age resistance to FeLV infection could be overcome by 
treating cats with adrenal corticosteroids and Schaller et al. 
(1978) found that the carcinogen, methylnitrosourea, could also 
overcome this age resistance.
8. Epidemiological situations of FeLV infections
As has been discussed previously, the incidence of infection 
with FeLV may be high within cat populations, with the virus being 
either horizontally transmitted in the saliva of persistently 
viraemic cats, or congenitally transmitted from mother to foetus.
There are two reasonably distinct epidemiological patterns of 
FeLV infection. The first involves closed multicat households such 
as breeding colonies. When a viraemic cat is introduced to these 
establishments almost all of the in-contact cats eventually become 
infected as indicated by the presence of anti-FOCMA antibodies in 
the sera of 90% of these cats (Hardy et al., 1973a). Kittens which 
are born in these households are exposed to the infection at a very 
early age and therefore run a high risk of developing viraemia. 
This outcome is also favoured by exposure of these kittens to 
frequent and high doses of the virus. The prevalence of persistent 
viraemia in these households is therefore very high. Jarrett et 
al. (1978a) reported that 40% of these cats were persistently 
viraemic and Hardy (1980b) found that 28% of cats in a household 
with FeLV were viraemic compared to 0% in households which had not 
been exposed to FeLV. The incidence of FeLV-related diseases is 
therefore also high but the majority of the cats which are not 
viraemic produce VNAs and are believed to be resistant to 
re-infection (Hardy et al., 1976a; Russell and Jarrett, 1978b). 
Russell and Jarrett (1978b) found that 42% of cats in these 
households had VNAs compared to only 4% of free range cats (see 
below).
In summary, in closed multicat households in which FeLV is 
enzootic, cats are exposed to frequent high doses of virus from a 
very early age. There is a high incidence of viraemia with 
associated disease and the prevalence of VNAs and anti-FOCMA 
antibodies is also high.
The second epidemiological situation involves free range cats 
in urban and suburban areas. Between 40% and 50% of these cats 
have anti-FOCMA antibodies (Rogerson et al. , 1975; Russell and
Jarrett, 1978b) indicating that exposure to the infection is 
frequent. However, the dose of virus transmitted is probably low 
compared to the situation described above. Urban cats are 
generally older than cats in multicat households when they are 
first exposed to the virus and therefore have developed an 
age-related resistance to the infection. Only 1% of urban cats
are persistently viraemic (Hardy et al., 1976a) and only 4% have
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VNAs in their serum (Russell and Jarrett, 1978b). The incidence of 
FeLV-related diseases in urban cats is therefore relatively low. 
It is possible that transiently viraemic cats which excrete virus 
for a short time are important in maintaining the cycle of 
infection in this community as well as the small number of 
persistently viraemic cats (Jarrett et al., 1982).
9. Control of FeLV infection
a) Test-and-removal programmes
Because of the rapid spread of FeLV through cats in multicat 
households and the incidence of persistent viraemia and disease 
which results, there is often a demand to adopt a means of 
control. An effective control programme which is in common use was 
first described by Hardy et al. (1976b) and involves a test and 
removal procedure.
In a single-cat household control is relatively easy. Once a 
cat has been identified as being viraemic it should be isolated 
from other cats in the area and retested after an interval of 3 
months. Three months should be long enough to allow most transient 
infections to become suppressed. However, if the cat is again 
viraemic on this second test it should be kept in isolation from 
other cats or even destroyed since its life expectancy is very 
short (McClelland et al., 1980). The household should then be 
cleaned with normal household detergents in order to inactivate any 
virus present, the litter tray and feeding bowls should be either 
disinfected or discarded, and an interval of 30 days should elapse 
before another cat is introduced.
A similar procedure is adopted in multicat households. 
Viraemic cats are identified and isolated and the house should be 
cleaned as above. Both the viraemic and the non-viraemic cats 
should be retested after 3 months and any new cases of viraemia 
should also be isolated. Cats which are negative on the second 
test but were positive on the first test remain in isolation until
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they are negative on two consecutive occasions. Cats which are 
negative on two consecutive tests can then be considered to be free 
from infection and can be bought or sold as desired. Cats which 
are positive on the two tets, however, should be eliminated from 
the household. All new cats which enter the house should be 
isolated and tested for FeLV and it would be advisable for owners 
of breeding stock to obtain a certificate stating that the cat is 
free from viraemia before going to stud.
Hardy et al. (1976b) thus successfully controlled the 
infection in many multicat households. After removal of viraemic 
cats, only 3 out of 657 uninfected cats became viraemic (0.46%) 
compared to 55 out of 284 (19.3%) which became viraemic when the 
viraemic cats were not removed. Similar results were obtained by 
Weijer and Daams (1978) using this method in the Netherlands.
b) Vaccination
It was thought for the following reasons that vaccination 
might be a possible method of controlling FeLV infections. 
Firstly, the virus is transmissible by contact (Hardy et al. , 
1973a; Jarrett et al., 1973b) and therefore the cycle of infection 
might be broken. Secondly, recovered cats develop neutralising 
antibodies (Jarrett et al., 1973b; 1977; Pedersen et al., 1977) and 
are resistant to reinfection with the virus. Thirdly, passively 
acquired antibody will protect cats from infection: maternally
derived antibody protected kittens from challenge (Jarrett et al., 
1977).
Experimental vaccines have been produced in several 
laboratories. Four types of vaccine have been described.
i) Vaccines derived from cells
The first attempts at vaccine production were by Jarrett et al. 
(1974) who described two cellularly derived vaccines. These 
consisted of either live or paraformaldehyde-inactivated lympho-
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blastoid cells of the FL74 line (Theilen et al., 1969). It was 
found that both vaccines induced anti-FOCMA antibodies and that 
cats vaccinated with the live cells were protected against 
challenge. Cats vaccinated with the inactivated cells were not 
challenged and therefore it is not known whether or not this 
vaccine was protective.
ii) Vaccines derived from virus
Both live and inactivated virus produced by FL74 cells have been 
used as vaccines (Pedersen et al., 1979; 1986). Although a
detectable antibody response was not found in vaccinated cats, 80% 
were found to be protected from challenge.
A similar type of vaccine was produced using the virus from 
tumour cells of the F422 line (Rickard et al., 1969). This vaccine 
consisted of paraformaldehyde-inactivated virus, and like the FL74 
vaccine described above, rendered 80% of the cats resistant to 
challenge in the absence of a detectable antibody response 
(Mahmoud, 1984).
iii) Subunit vaccines
The first subunit vaccine was produced by Salerno et al. (1978) 
using the gp70 from purified virus. Again, there was no antibody 
response in these cats. Unfortunately the results of these 
experiments are inconclusive since the cats used in the study were 
too old to be effectively challenged.
Pedersen et al. (1986) produced a similar gp70 subunit vaccine 
which was found to be ineffective because rather than protecting 
cats it resulted in an enhancement of the challenge.
A second type of subunit vaccine consisting of the gp70/85 of 
virus produced by either FL74 or F422 cells has been developed 
(Osterhaus et al. , 1985). This vaccine was prepared by combining 
gp70/85 from disrupted purified FeLV with an immunostimulating
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complex (ISCOM) derived from saponin. This vaccine resulted in 
100% protection from challenge and is as yet the only vaccine which 
has induced a detectable neutralising antibody response in the 
vaccinates. It is likely that the success of this vaccine is due 
to the efficient way in which the ISCOM presents the gp70 to the 
immune system.
iv) Soluble tumour cell vaccine
This type of vaccine was produced by culturing FL74 cells in 
serum-free medium which resulted in the cell surface components 
being shed into the culture fluid (Olsen et al., 1976). These
components were then inactivated, concentrated and used as a 
vaccine. Again, there was no detectable neutralising antibody 
response produced in these cats. These inactivated FL74 cell 
surface components are the basis of a commercial vaccine which is 
currently available in the United States and some European
countries (Leukocell; Norden) and is claimed to give between 70 and 
80% protection against challenge.
10. FeLV latency
Until recently it was thought that there were only two
outcomes of infection with FeLV; persistent viraemia or recovery. 
However, Post and Warren (1980) discovered that a third possible 
outcome was latency. These authors treated 4 non-viraemic cats 
with corticosteroids daily for 21 days in an attempt to reactivate 
a latent infection. One of these cats had been viraemic initially 
but had eliminated its viraemia after passive immunotherapy, and 
another 2 of the cats had been exposed to viraemic cats and were 
presumed to have recovered from infection. The fourth cat was not 
known to have been exposed to FeLV.
After treatment infectious virus was isolated from the blood
of 2 of these cats, although 3 were positive for antigen by ELISA
and all 4 were positive for antigen in neutrophils by immuno­
fluorescence.
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This work showed that cats which appear to have recovered from 
infection may harbour a latent infection which in some cases can be 
reactivated by corticosteroid therapy.
These results were confirmed by Rojko et al. (1982) when 
viraemia was produced in all of 5 latently infected cats by the use 
of corticosteroid therapy twice weekly for 4 weeks. The viraemia 
was persistent in only 2 of these cats. These authors also found 
that virus could be reactivated and isolated from cultured bone 
marrow of 8 out of 10 exposed immune cats compared to none of 4 
unexposed cats. However virus could not be isolated from freshly 
obtained uncultured marrow.
By carrying out immunofluorescence on cultured marrow Rojko et 
al. (1982) found that viral antigen was present in differentiating 
myelomonocytic precursor cells but not in mature macrophages or 
granulocytes. The site of the latent virus was therefore 
identified as being in the bone marrow, probably in myelomonocytic 
precursor cells.
The possible involvement of latent FeLV in lymphosarcomas in 
non-viraemic cats has been studied (Rojko et al., 1982; Madewell 
and Jarrett, 1983). The results from the 2 groups of workers 
differ. Rojko et al. (1982) isolated virus which had been 
reactivated from cultured marrow from both of 2 cats whereas 
Madewell and Jarrett (1983) failed to isolate virus from 2 similar 
cases. The possible role of latent FeLV in these tumours is 
therefore unresolved.
Madewell and Jarrett (1983) reported that FeLV could be 
reactivated from the cultured bone marrow cells of 9 of 16 
ostensibly recovered cats 36 weeks after exposure to viraemic 
cats. All 9 of these cats had VNAs and anti-FOCMA antibodies. At 
any one time therefore a considerable proportion of the cats in a 
FeLV-positive multicat household may harbour latent infections.
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11. Aims of the present study
Because of the potentially large numbers of latent infections 
in multicat households it was of importance to investigate the 
significance of these infections and this is the subject of this 
thesis. The major aims of the study were:
a) to develop a reliable method to identify latently infected 
cats,
b) to determine the prevalence and duration of the latent 
state in multicat households following exposure of cats to 
natural FeLV infection,
c) to determine the clinical and epidemiological significance 
of latency, particularly in multicat households, and
d) to investigate the factors which maintain FeLV in the 
latent state.
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CHAPTER 2 
GENERAL MATERIALS AND METHODS
Ceils
Monolayer cell cultures used in this study were feline embryo 
fibroblast cells of the FEA strain (Jarrett et al., 1973c) and FEA 
cells chronically infected with FeLV of subgroup A (FEA/FeLV-A) or 
subgroup B (FEA/FeLV-B) (Jarrett et al., 1972) which were 
continuously expressing infectious virus. The FEA/FeLV-A cells 
were infected with the Glasgow-1 strain (FeLV-A/Glasgow-1) (Jarrett 
et al., 1972) and the FEA/FeLV-B cells were infected with the Sarnia 
strain (FeLV-B/Sarma). Clone 81 (c81) cells were feline cells
derived from the CCC line which carry the genome of a murine 
sarcoma virus (Fischinger et al., 1974).
The feline tumour cell line, FL74, which was derived from a 
renal lymphosarcoma (Theilen et al., 1969) was used. This culture 
is composed of transformed T-lymphocytes which express FeLV of 
subgroups A, B and C and grow in stationary suspension.
Cell culture
Cells were routinely grown in 25 cm^, 80 cm^ or 175 cm^ 
plastic flasks (Nunc) in an atmosphere of 5% CO2 in air and were 
incubated at 37°C. Cells grown in plates were cultured in a LEEC 
GA2 incubator with a fully humidified atmosphere of 5% CO2 in air 
at 37°C.
The foetal calf serum (FCS) (Gibco) used for culturing cells 
was heated to 56°C for 30 minutes in order to remove complement.
a) Monolayer cells
FEA, FEA/FeLV-A, FEA/FeLV-B and c81 cells were grown in 
Dulbecco's modified Eagle’s Minimal Essential Medium (DMEM) (Gibco) 
supplemented with 10% FCS, 2mM L-glutamine and 400 units/ml of 
penicillin-streptomycin (DFC10).
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Three times per week the culture fluid was removed and the 
adherent cell monolayers were dispersed by rinsing three times in a 
solution of 0.01% trypsin in 0.02% EDTA. The cells were 
resuspended in DFC10 and subcultured at a ratio of 1:4.
b) Suspension cells
FL74 cells were grown at a concentration of 8 x lO^/ml in a 
medium consisting of equal volumes of Leibovitz L-15 medium (Gibco) 
and McCoys 5a medium (Gibco) supplemented with 10% FCS, 2mM 
L-glutamine and 400 units/ml of penicillin-streptomycin (LM 
medium). They were subcultured and resuspended at this
concentration twice weekly.
Experimental cats
Cats which were free from infection with FeLV were bred in a 
closed colony and were housed in huts, either in groups or 
individually. Up to 8 cats were housed in a hut with a floor area
of approximately 3m^, and between 9 and 20 cats were housed in a
hut with a floor area of approximately 7.5m2. Fig. 2.1 shows 
examples.
Infection of cats
The virus used to infect cats was FeLV-A/Glasgow-1. The dose 
of virus and the route of administration for each cat used in this 
study are summarised in Table 2.1 and described in detail in each 
Chapter.
Production of FeLV-A/Glasgow-1 for infection of cats
The virus was produced from FEA/FeLV-A cells which were
chronically infected with FeLV-A/Glasgow-1.
One million FEA/FeLV-A cells were plated in 9 cm sterile
plastic petri dishes (Nunc) in 10 ml of DFC10 supplemented with 1%
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Examples of cat huts.
a. To house up to 8 cats.
b. To house between 9 and 20 cats
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TABLE 2.1 Cats used in this study
Cat No. Virus status* Method of infection
1
2
3
4
5
6
7
8 
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28 
29
V
V
V 
L 
L 
L 
L 
L 
L 
L 
L 
L 
R 
R 
R 
R 
R 
R 
R
L ^  R
Natural exposure FeLV-A/Glasgow-1
Intraperitoneal FeLV-A/Glasgow-1 
8 x 10^ fiu 
Oronasal FeLV-A/Glasgow-1 
1 x 1q 6 fiu
Vaccinated oronasal FeLV-A/Glasgow-1
1 x 1 06 fiu
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TABLE 2.1 (Continued)
Cat No. Virus status1 Method of infection
30 L Vaccinated oronasal FeLV-A/Glasgow-1
1 x 106 fiu
31 L
32 L Natural exposure FeLV-A/Glasgow-1
33 T Natural exposure to cats with latent
34 T FeLV-A/Glasgow-1
35 T
36 T " " "
37 T "
38 T ..
^  iji M  11 *•
40 T
41 L Oronasal FeLV-A/Glasgow-1 1 x 10^ fiu
42 L . . . .  ..
43 L V a c c i n a t e d o r o n a s a l  FeLV-A/Glasgow-1
1 x 106 fiu
44 L M "
45 L
46 L Oronasal FeLV-A/Glasgow-1 1 x 10^ fiu
47 L
48 L
49 U
50 U
51 U
52 V Oronasal FeLV-A/Glasgow-1 1 x 10^ fiu
53 v "
54 R Oronasal FeLV-A/Glasgow-1 1 x 10^ fiu
55 R "
56 R (field) Natural exposure FeLV
57 R (field)
58 R (field)
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TABLE 2.1 (Continued)
Cat No. Virus status^ Method of infection
59 R (field) Natural exposure FeLV
60 U
61 U
62 V Oronasal FeLV-A/Glasgow-1 1 x 10^ fiu
63 V Subcutaneous FeLV-A/Glasgow-1 1.3 x 106 fiu
64 u
Key to Table 2.1
1. Virus status: L = latently infected; V = viraemic;
R = recovered; U = uninfected;
T = tracer
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amphotericin B and 1% lincomycin hydrochloride (DFC10-AL). These 
plates were incubated at 37°C.
After 48 hours the culture fluid was harvested and spun at 
2000 rpm for 10 minutes. The supernatant fluid was then passed 
through a 0.45 pm sterile filter (Nalgene). The virus was concen­
trated in an Amicon hollow fibre concentrator (CH4) using an HI 
MP01 cartridge with a nominal molecular weight cut-off of 100,000.
The concentrated virus was then distributed into vials and 
stored at -70°C prior to use.
Virus infectivity assay
To determine the infectivity of each batch of virus a focus 
assay was used.
A mixture of 2 x 10^ FEA cells and 2 x 10^ c81 cells was
plated in 5 cm sterile plastic petri dishes (Nunc) in 2 ml of 
DFC10-AL. These cultures were incubated overnight at 37°C.
The virus was recovered from -70°C and fivefold dilutions were 
made in DFC10-AL supplemented with 4 pg/ml of polybrene in order to 
aid virus adsorption. The medium was removed from the plates and 
an inoculum of 1.0 ml of virus dilution was added. Each dilution 
was tested in duplicate. The virus was adsorbed for 90 minutes at 
37°C after which the medium was replaced with 4 ml of DFC10-AL.
The plates were then incubated for a further 3-4 days when the
medium was replaced with 4 ml of fresh DFC10-AL. After 7-10 days, 
the foci in plates which contained approximately 20 foci were
counted. From these counts the titre of virus was obtained and 
expressed as focus inducing units (fiu) per ml.
Blood samples
Blood samples were obtained from experimental cats by jugular 
venepuncture. Samples were taken into heparin coated tubes for 
detection of viral antigen and infectious virus, and into plain 
tubes for serological tests. Plasma and serum were separated by 
centrifugation at 2000 rpm for 10 minutes. Plasma was stored at 
-70°C and serum at -20°C.
Detection of viral antigen
FeLV p27 antigen was detected in the plasma of cats using an 
enzyme-linked immunosorbant assay (ELISA) kit (Leukassay-F; C-Vet). 
The test was carried out according to the methods of Jarrett et
al. (1982). A volume of 50 pi of plasma was tested.
Detection of infectious virus
Infectious FeLV in the plasma of cats and in cell culture 
fluids was detected by a modification of the virus isolation test 
described by Jarrett et al. (1982). This test resembles the focus 
assay described above. A mixture of 2 x 10^ FEA cells and 2 x 104 
c81 cells was plated in 5 cm petri dishes in 2 ml DFC10-AL with 4 
pg/ml of polybrene which were incubated overnight at 37°C. A volume 
of between 0.5 ml and 1 ml of sample was added and incubated at 
37°C for 90 minutes to allow adsorption of virus. The medium was 
then replaced with 4 ml of DFC10-AL and incubated for 3 days. 
After this time, the medium was again replaced with a fresh 4 ml of 
DFC10-AL and the plates were incubated for a further 3-4 days. The 
presence of infectious virus was observed as foci of transformed 
cells on a background of a confluent FEA/c81 cell monolayer. Fig.
2.2 shows photographs of uninfected FEA/c81 cell mixture (a), and a
FEA/c81 cell mixture transformed by FeLV (b).
Detection of virus neutralising antibodies
Virus neutralising antibodies (VNAs) to FeLV-A in the serum of
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FIG. 2.2 Virus isolation.
a. An uninfected FEA/c81 cell monolayer.
b. A FEA/c81 cell monolayer transformed with FeLV.
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cats and in mouse monoclonal antibodies (MCAs) to FeLV proteins 
were detected by a modification of the methods described by Russell 
and Jarrett (1978a).
A volume of 0.5 ml of medium containing 1 x 10^ FEA/FeLV-B 
cells was plated into each well of 24-well sterile plastic 
multiwell trays (Nunc). The medium was DMEM supplemented with 20% 
FCS, 2mM L-glutamine, 400 units/ml of penicillin-streptomycin, 1% 
amphotericin B and 1% lincomycin hydrochloride (DFC20-AL). The 
cells were incubated for 2 hours at 37°C. Twelve twofold serum 
dilutions were made in Leibovitz L-15 medium supplemented with 5% 
FCS, 2 iriM L-glutamine, 400 units/ml of penicillin-streptomycin, 1% 
amphotericin B and 1% linocmycin hydrochloride (dilution medium). 
These dilutions started at a concentration of 1:2 and 50 pi volumes 
were made of each in sterile plastic round-bottomed 96-well micro- 
titre plates (Nunc). A volume of 50 pi of a FeLV-A/Glasgow-1 
pseudotype of Moloney murine sarcoma virus (Russell and Jarrett, 
1976) was added to each well. Twelve twofold dilutions of the 
virus itself were included as a control. The plates were then 
incubated at 37°C for 2 hours to allow virus neutralisation to take 
place.
After the incubation period, a volume of 25 pi of the reaction 
mixture was added to the wells containing FEA/FeLV-B cells. The 
cells were then incubated as before. After 24 hours the medium was 
removed and 8 x 10^ FEA cells in 1 ml of DFC20-AL were added to 
each well. The plates were then incubated for a further 3-4 days. 
The presence of virus was identified as foci of transformation on 
the cell sheet. The VNA titre was taken as the highest dilution of 
serum which caused a 75% reduction in the number of foci compared 
to the virus control.
Detection of anti-FOCMA antibodies
F0CMA is an antigen demonstrable on the plasma membrane of 
FeLV-infected leukaemic cells (Essex et al. , 1971b). The presence
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of antibodies directed against this antigen in cat serum is
believed to be a sensitive indicator of exposure to FeLV. Anti- 
FOCMA antibodies were detected by a live cell immunofluorescence 
(IF) test using the FL74 cell line. The method described here is a 
modification of that described by Essex et al. (1971b).
FL74 cells were washed twice in serum-free Leibovitz L-15 
medium by centrifugation at 1000 rpm for 5 minutes and were
suspended in fresh medium at a concentration of 2 x 1 0 6 /mi. a 
volume of 25 pi of this suspension was placed in each 7 mm well of 
a 96-well teflon-coated glass slide (Henley-Essex). The slides 
were incubated at 37°C in a moisture chamber for 30 minutes to
allow the cells to adhere to the glass.
Eight doubling dilutions in 25 pi volumes of the sera to be 
tested were made in serum-free Leibovitz L-15 medium in 96-well 
U-bottomed plastic microtitre plates. When the FL74 cells had
adhered to the glass 25 pi volumes of each serum dilution were 
added and the slides were incubated as above for 1 hour.
After this time the slides were gently washed twice in 
phosphate buffered saline (PBS) at room temperature. The slides 
were then flooded (approximately 30 pl/well) with goat-anti-cat IgG 
conjugated with fluorescein isothiocyanate (Miles) at a dilution of 
1:30 in serum-free Leibovitz L-15 medium. After a further 
incubation of 1 hour the slides were washed as above and kept moist 
in PBS. They were examined for membrane fluorescence under a Leitz 
Orthoplan microscope with an ultraviolet light source using a x 25 
water immersion objective. The antibody titre was taken as the 
highest dilution of serum in which more than approximately 25% of 
the cells showed membrane fluorescence (Fig. 2.3).
Oropharyngeal swabs
Saliva was obtained for detection of infectious virus in the 
mouth of cats. The tonsillar area was carefully swabbed with a 
sterile wooden cotton-tipped swab (Exogen). The tip was broken off
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FIG. 2.3 Demonstration of anti-FOCMA antibodies in a cat serum by 
the presence of membrane IF on FL74 cells. The
photographs were taken using both visible and
ultraviolet light sources.
The arrows point to cells showing membrane fluorescence.
Magnification x 250
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into a sterile plastic bottle (Sterilin) containing 3 ml Leibovitz 
L-15 medium supplemented with 5% FCS, 2 mM L-glutamine, 400 units/ 
ml of penicillin-streptomycin, 1% amphotericin B and 1% lincomycin 
hydrochloride (transport medium). Gross debris was removed by 
centrifugation of the fluid at 2000 rpm for 10 minutes and the 
supernatant was stored at -70°C prior to testing for infectious 
virus.
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CHAPTER 3 
DETECTION OF LATENCY
INTRODUCTION
Latent FeLV infections may be detected by treating latently 
infected cats with high doses of corticosteroids. Virus becomes 
reactivated in a proportion of the cats which develop a persistent 
viraemia. It was in this way that Post and Warren (1980) 
discovered the latent state. In their study 4 apparently recovered 
cats were treated with 1 mg of dexamethasone and 5 mg of 
prednisolone daily for 21 days, except on days 10, 11 and 12 when 
no drugs were given. Two of these cats became viraemic as 
determined by virus isolation from plasma.
Rojko et al. (1979b) suggested that the establishment of 
regressive (recovery) versus progressive (viraemia) infection in 
vivo was sensitive to corticosteroid therapy and that cats which 
were thus treated had an increased risk of developing viraemia. 
The effect of corticosteroids on latent FeLV infections was tested 
both in vivo and in vitro (Rojko et ai. , 1982). Five latently 
infected cats were treated with 10 mg/kg of methylprednisolone 
twice weekly for 4 weeks and 2 of them became persistently 
viraemic. Pedersen et al. (1984) produced persistent viraemia in 
only 5 out of 49 cats with known latent infections when they were 
treated with 10 mg/kg of methyprednisolone once weekly for 4 
weeks. These authors also suggested that the ease of reactivation 
was dependent on the strain of virus with which the cats were 
infected. Cats which were infected with the Rickard strain became 
viraemic more frequently than cats infected with the Snyder-Theilen 
strain.
It is clear that high doses of corticosteroids can reactivate 
latent infections in some cases to produce viraemia although the 
mechanism of reactivation is unclear. Two of the undesirable 
effects of long-term corticosteroid therapy are the occurrence of 
degenerative changes in the bone marrow and immunosuppression. 
Therefore the fact that latent FeLV can be reactivated from marrow 
following such therapy may be due to these side effects or may be
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due to a primary effect on virus expression. The two- or threefold 
increase in virus production reported by Rojko et al. (1982) when 
latently infected cells were treated with corticosteroids in vitro, 
was thought to be due to a direct effect on viral transcription.
The most reliable and commonly used method to detect latent 
FeLV infections is the culture of aspirated bone marrow cells which 
leads to reactivation of the latent virus (Rojko et al., 1982; 
Madewell and Jarrett, 1983; Pedersen et al., 1984). Virus cannot 
be detected in freshly aspirated marrow. Upon culture of the 
marrow, reactivated virus has been detected in three ways: 
firstly, by isolation of infectious FeLV which is released into the 
culture fluids (Rojko et al. , 1982; Madewell and Jarrett, 1983; 
Pedersen et al., 1984); secondly, by detection of FeLV p27 antigen 
in the culture fluids by ELISA (Pedersen et al. , 1984) and thirdly, 
by detection of p27 in the cytoplasm of infected cells by fixed 
cell IF (Rojko et al., 1982).
In this study latently infected animals were detected by the 
culture of aspirated bone marrow. Corticosteroid therapy was not 
used due to the low proportion of latently infected cats which 
reactivate virus (Pedersen et ai., 1984). It would appear that the 
chances of achieving reactivation are much less than the chances of
causing other secondary infections resulting from the immuno­
suppression produced by prolonged and high doses of corticosteroids
(N.C. Pedersen, personal communication).
In the present study freshly aspirated latently infected
marrow was tested for the presence of FeLV by virus isolation in a 
similar way to that described by Madewell and Jarrett (1983). In 
addition two other methods were used: live cell IF which detects
FeLV gp70 antigen on the cell surface and fixed cell IF which 
detects p27 in the cytoplasm. After culture reactivated virus was 
detected in the culture fluids by virus isolation and by detection 
of p27 antigen in the cytoplasm of cells by fixed cell IF. Also, 
to obtain a quantitative assessment, the proportion of latently 
infected cells in the marrow was determined by an infectious centre 
assay.
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MATERIALS AND METHODS
Collection of bone marrow cells
Cats were heavily sedated prior to bone marrow biopsy by an 
intramuscular inoculation of 25 mg/kg ketamine hydrochloride 
(Vetalar: Parke Davis). The fur covering the gluteal region was 
closely clipped and the skin was disinfected with 0.5% Hibitane 
(ICI) in 70% methanol. Femoral shaft bone marrow biopsies were 
obtained via the trochanteric fossa (Fig. 3.1) by aspiration 
through sterile 18 gauge disposable Illinois pattern bone marrow 
biopsy needles (Kormed) (Fig. 3.2) using 10 ml syringes. The 
marrow was collected into 3 ml of Alpha Minimal Essential Medium
(Gibco) supplemented with 10% FCS, 2 mM L-glutamine, 400 units/ml
£
penicillin-streptomycin, 10“ m  hydrocortisone succinate (AFC10) 
and 1% preservative-free heparin (Pularin) (collection medium).
Culture of bone marrow cells for detection of latent FeLV
Single cell suspensions of bone marrow cells were prepared in
10 ml of collection medium by passing the cells through a 21 gauge
needle and then through a 23 gauge needle. The suspension was
centrifuged for 10 minutes at 2000 rpm. The bone marrow supernatant
(BMSN) was decanted and stored at -70°C for future virus
isolation. The cell pellet was resuspended in 10 ml of 0.83%
ammonium chloride and incubated on ice for 5 minutes in order to
lyse the red blood cells. Following a second centrifugation at
2000 rpm for 10 minutes the supernatant was discarded and the cell
pellet was resuspended in 10 ml Alpha Minimal Essential Medium
supplemented with 20% FCS, 2mM L-glutamine, 400 units/ml penicillin
£
-streptomycin and 10” M hydrocortisone succinate (AFC20). The 
cells were then counted and were cultured in 10 ml AFC20 at a 
concentration of 2 x 10^/ml in 25 cm2 plastic flasks. Duplicate 
cultures were prepared for each biopsy and were incubated at 37°C.
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FIG. 3.1 Femoral shaft bone marrow biopsy. Sedation was achieved 
using ketamine hydrochloride. The biopsy needle gains 
entry to .the femoral shaft via the trochanteric fossa. 
Bone marrow is aspirated using a 10 ml syringe.
4*
FIG. 3.2 Bone marrow biopsy needle.
a. Entire needle.
b. Fragmented needle showing individual components.

The cultures were fed each week by replacing 5 ml of medium 
with fresh AFC20. The medium which was removed was stored at -70°C 
prior to testing for infectious virus,
IF on bone marrow prior to culture
a) Live cell IF
Single cell bone marrow suspensions were washed twice in 
serum-free Leibovitz L-15 medium and were resuspended in this 
medium at a concentration of 2 x 1 0 6 /ml. a volume of 25 pi of this 
suspension was placed on each 7 mm well of an 8-well teflon coated 
glass slide (Flow Laboratories). The slides were incubated at 37°C 
in a moisture chamber for 30 minutes to allow the cells to adhere 
to the glass. A mouse MCA which neutralises FeLV-A (4611 E2;
Vedbrat et al., 1983) was used at a dilution of 1:100 in Leibovitz 
L-15 medium and a volume of 25 pi was then added to each well. The 
slides were incubated as above for 1 hour and were then gently 
washed twice in PBS for 2 minutes. A volume of 25 pi of sheep anti­
mouse Ig linked to fluorescein isothiocyanate (Amersham Inter­
national) at a dilution of 1:100 in Leibovitz L-15 medium was added 
to each well and the slides were incubated for 1 hour at 37°C. The 
slides were then washed as above and the cells were examined for 
the presence of membrane IF as described for the anti-FOCMA 
antibody test. The test described above detects the envelope 
glycoprotein (gp70) on the surface of cells which are expressing 
FeLV.
b) Fixed cell IF
Bone marrow cell suspensions were prepared as above and 
resuspended in serum-free Leibovitz L-15 medium at a concentration 
of 2 x 10^/ml. Three drops of this suspension were spun onto glass 
slides at 1500 rpm for 5 minutes in a Cytospin II cy to centrifuge 
(Shandon). The cells were then dried, fixed in absolute methanol 
at room temperature for 5 minutes, dipped in water and dried.
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A volume of 25 pi of rabbit anti-FeLV serum (see below) which 
was diluted 1:40 in PBS was added to each cytospin preparation. 
The slides were then incubated at 37°C in a moisture chamber for 2 
hours. Following this incubation the slides were washed twice in 
PBS at room temperature for 2 minutes, dipped in water and dried.
A volume of 25 pi of donkey anti-rabbit IgG conjugated to fluo 
-rescein isothiocyanate (Amersham International) diluted 1:40 in 
PBS was added to each slide which was then incubated as above for 1 
hour. The slides were again washed in PBS, dipped in water and 
dried. The cells were examined for the presence of cytoplasmic FeLV 
antigen under a microscope with an ultraviolet light source as 
above. This test detects antigen in the cytoplasm of cells which 
are actively infected with FeLV.
Production of rabbit anti-FeLV antibody
Antibody to FeLV gag proteins was obtained from 0. Jarrett. 
Antisera were raised in 4 rabbits immunised with purified FeLV-A/ 
F422 (Rickard et al., 1969) disrupted with triton X-100. Anti­
bodies were purified from pooled sera by affinity chromatography 
using a column of Sepharose 4B linked to FeLV-A/F422 disrupted by 
NP40.
Culture of bone marrow cells for IF
Single cell suspensions of marrow were prepared as described 
above in AFC20 at a concentration of 2 x lO^/ml. A volume of 0.3 
ml of this suspension was plated into each well of 8-well 
Flaskettes (Lab-Tek) (Fig. 3.3) and incubated at 37°C. At 3-day 
intervals half of the medium was removed and replaced with fresh 
AFC20. Bone marrow was grown in this manner for 10 days after 
which time the presence of viral antigen could be detected in the 
cytoplasm of latently infected cells by fixed cell IF.
Preparation of Flaskette cultures for IF
The culture fluid was carefully pipetted from the chambers of
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Photograph of an 8-well Flaskette.
a. Flaskette in use for cell culture showing individual 
chambers.
b. Flaskette slide prepared for IF after removal of 
the chamber walls.
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the Flaskette. The plastic walls of the chambers were removed 
leaving the bone marrow cells adherent to the glass slide. The 
slides were gently washed twice in PBS at room temperature for 2 
minutes and then fixed in absolute methanol at room temperature. 
They were then dipped in water and air dried. Fixed cell IF was 
carried out on the Flaskette slides using 50 pi volumes of reagents 
per well.
Proportion of latently infected cells in the bone marrow
a) Experimental cats
Bone marrow was taken from 8 latently infected cats in order 
to assess the proportion of cells in the marrow which was harbour­
ing latent virus. Four of these cats (cats 21-24) had received an 
oronasal dose of 1 x 10^ fiu of FeLV-A/Glasgow-1 in 1 ml Leibovitz 
L-15 medium at 16-20 weeks of age. Three cats (cats 29-31) had 
received an experimental FeLV vaccine which was given by 
intramuscular injection at 8 and 11 weeks of age. Briefly, this 
vaccine was made from FeLV-A/F422 inactivated with 0.02% 
paraformaldehyde and adjuvanted with aluminium hydroxide and 
incomplete Freund’s adjuvant (Mahmoud, 1984). The cats were then 
challenged oronasally with 1 x 10^ fiu of FeLV-A/Glasgow-1 at 14 
weeks of age. These cats did not become viraemic but were latently 
infected. The eighth cat, cat 32, was born in the multicat 
household detailed in Chapter 4 and after exposure to the viraemic 
donor cats developed a latent infection.
One recovered cat (cat 28) and 3 viraemic cats (cats 25-27) 
were included as controls. Cats 27 and 28 had received the 
experimental FeLV vaccine and had been challenged as described 
above. Cat 27 developed a persistent viraemia, whereas cat 28 
resisted challenge, had no evidence of latent infection and was 
therefore said to be "recovered”. Cats 25 and 26 had been given 1 
x 106 fiu 0f FeLV-A/Glasgow-1 oronasally in 1 ml Leibovitz L-15 
medium at 16-20 weeks of age. The sources of infection of these 
animals are summarised in Table 2.1.
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b) Infectious centre assay
A mixture of 4 x 10^ FEA cells and 4 x 104 c81 cells were 
co-cultivated in 5 cm petri dishes in a volume of 3 ml DFC10-AL and 
incubated for 4 hours at 37°C. Single cell suspensions of bone 
marrow were prepared as described above but were finally suspended 
at a concentration of 4 x lO^/ml in DFC10-AL. Five tenfold 
dilutions were made and 1 ml of each dilution was added to the 
FEA/c81 assay plates. Duplicate plates were used for each cell 
concentration.
The plates were incubated for 3 days after which time the 
medium was removed and replaced with a fresh 4 ml DFC10-AL. After a 
further incubation for 3 days the plates were examined for the 
presence of foci of transformed cells, which were counted.
The reproducibility of each assay was assessed by plating 
FEA/FeLV-A cells onto the FEA/c81 mixture. The FEA/FeLV-A cells 
were known to be continuously producing virus. Five twofold 
dilutions were made with a highest concentration of 50 cells/ml. 
The assay proceeded as above.
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RESULTS
Culture of bone marrow cells
Bone marrow cells grew as an adherent cell monolayer. After 
one week in culture small colonies of fibroblasts developed which 
gradually coalesced, so that by 2 weeks in culture the fibroblasts 
were confluent. Also by this time large granulated cells were 
present and areas of more mature myeloid cells could be identified 
(Fig. 3.4). The presence of mature myeloid cells indicated that 
myeloid stem cells in the marrow were capable of differentiation in 
vitro. Cultures were maintained for 4 weeks.
Evidence for lack of FeLV expression in freshly aspirated bone 
marrow from latently infected cats
Detection of FeLV expression in freshly aspirated bone marrow 
cells from latently infected cats was attempted in 3 ways: by
virus isolation from the BMSN; by live cell IF to detect gp70 on 
the surface of cells, and by fixed cell IF to detect p27 in the 
cytoplasm of cells. A comparison of the results obtained from 
carrying out these tests on marrow from latently infected or 
viraemic cats is given in Table 3.1.
Infectious virus was not isolated from the BMSN of any of 26 
latently infected cats used in this study but was isolated from all 
of 8 viraemic cats used. In 12 of these cats live cell IF failed 
to detect gp70 on the surface of latently infected cells and fixed 
cell IF failed to detect p27 in the cytoplasm. By contrast, 
between 1 and 10% of cells from viraemic cats were expressing gp70 
(0. Jarrett; personal communication) and almost all cells contained 
p27 (Fig. 3.5).
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FIG. 3.4 Bone marrow culture.
a. Sparse colony of fibroblasts visible after one week 
in culture.
b. Confluent monolayer of fibroblasts after 2 weeks in
culture. The photograph also demonstrates the
presence of large granulated cells (arrowed).
c. Colony of differentiated myeloid cells (arrowed)
seen after 2 weeks in culture.
Magnification x 100
•*
O9
»
• *' & >  -£• 0
©'
*  , ©  *
©
€> ©  
<*
o
<r ©  &
&
o
•Cj
6
vet*
G
w o •w1
©
t?
*> €re
o _ vT °
• $' * p?
/
©  9 I
° o °  /5 VJ o>
7  * 9
© '  2) <i?r-» '
©
r  0
<? 0
e>
oj0
• «r » -
j ©  G
€
'O o9
/O
<3 @ <s V  ^
° ®  ia 0
- O
#
~<0 . - O ' -  JCJ v o 
© *
Q  • 7
I?
o
,; •/ • 
fr
■ '" r. ?P
° * * °A& °
a
|>c
"'C-c^'
, ■»
33s
y&
.<iv»
sg> &  •
&
r*'.*o', - yi
€>
.•^ ■ {
49
TABLE 3.1
Detection of FeLV expression in freshly aspirated bone marrow 
from latently infected versus viraemic cats
Virus status
Test used______________________Latently infected___________Viraemic
Virus isolation^ - +
from BMSN
Live cell IF2 0 1 - 10%
gp70 detection
Fixed cell IF2 0 = 100%
p27 detection
1 + virus isolated
- virus not isolated
2 Figures given are percentage of total cells showing IF
FIG. 3.5 IF on freshly aspirated bone marrow from a viraemic cat.
a. Live cell IF demonstrating the presence of gp70 on 
the cell surface. The arrow indicates a positive 
cell.
b. Fixed cell IF demonstrating the presence of p27 in 
the cytoplasm of cells. Nearly all of the cells are 
positive.
Magnification x 500
t4
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Evidence for reactivation of FeLV from bone marrow cells from
latently infected cats following culture
a) Virus isolation from culture fluids
Samples of cell culture fluid were tested at weekly intervals 
for the presence of infectious virus. In almost all cases it was 
found that latent virus was reactivated and could be isolated from 
the culture fluid within 2 weeks of establishment of the culture. 
It was extremely unlikely that the bone marrow harboured a latent 
infection if reactivation had not occurred after 4 weeks in 
culture. Table 3.2 shows the results of a typical experiment in 
which bone marrow from the cats in the multicat household described 
in Chapter 4 were cultured and tested at weekly intervals for the 
presence of infectious virus. These results were obtained from 
biopsies taken 88 weeks after the cats were naturally exposed to 
FeLV (see Chapter 4). Cats 2 and 3 were persistently viraemic 
since infectious virus could be isolated from their plasma and
BMSN, and 9 cats (cats 5, 6, 7, 11, 12, 15, 17, 18 and 19) were
believed to have recovered from exposure since infectious virus
could not be detected in plasma, BMSN or in cell culture fluids 
after culture for 4 weeks.
The remaining 6 cats (cats 4, 8, 9, 10, 14 and 16) were
believed to be latently infected since infectious virus could not 
be detected in plasma or BMSN but could be detected after culture 
of bone marrow. Three of these latter 6 bone marrow cultures 
contained reactivated virus within 1 week of culture, 2 within 2 
weeks, and the sixth within 3 weeks. Both the latently infected 
and recovered cats had VNAs to FeLV-A in their sera.
b) Fixed cell IF
After a latently infected marrow had been in culture for 6 
days group specific antigen could be detected in individual cells 
by IF. The proportion of antigen-containing cells gradually 
increased so that by 8 days small foci of infection could be seen
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TABLE 3.2
Detection of latently infected bone marrow
Virus isolation from bone marrow culture^ 
Week 1 Week 2 Week 3 Week 4
Cat No. V BMSN A B A B A B A B VN/
2 + + + + ' + + + + + +
3 + + + + + + + + + + -
4 - - + + + + + + + + +
5 - - - - - - - - - - +
6 - - - - - - - - - - +
7 - - . - - - - - - - - +
8 - - + + + + + + + + +
9
10 _ _
+ + + + + +
+
+ + +
+
11 - - - - - - - - - - +
12 - - - - - - - - - - +
14
15
— — — — + + + + + + +
+
16 - - - - + + + + + + +
17 - - - - - - - - - - +
18 - - - - - - - - - - +
19 — - — -  ■ — — — — — — +
1 A and B are duplicate cultures made from one biopsy.
V = virus isolation from blood
BMSN = virus isolation from bone marrow collecting medium
+ = virus isolated
- = virus not isolated.
VNA = presence of virus neutralising antibodies to FeLV-A. 
Where no result is given the test was not done.
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and by 10 days most of the cells contained antigen. Fig. 3.6 shows 
IF carried out on a latently infected bone marrow after being 
cultured for 8 and 10 days.
Proportion of latently infected cells in the bone marrow
Each infectious centre was interpreted as representing one 
infected cell. In every assay essentially all of the FEA/FeLV-A 
cells plated registered as infectious centres indicating that the 
assay was an effective method of detecting virus-producing cells.
The number of infectious centres produced per 1 x 10^ bone 
marrow cells plated in the assay are shown in Table 3.3. The
proportion of infectious centres produced by latently infected 
marrow was found to be very low and variable between cats, ranging 
from 3 to 400 per 1 x 10^ cells plated (0.0003 to 0.04%). The bone
marrows from viraemic cats produced many infectious centres,
ranging from 6 x 10^ to 1.2 x 10^ per 1 x 10^ cells plated (0.6 to
12%). Infectious centres were not found in the marrow from the 
recovered cat. The foci produced by the latently infected bone 
marrow were the same size as those produced by the marrow of the 
viraemic cat and by FEA/FeLV-A cells indicating that under these 
conditions reactivation of latent virus had occurred within a short 
time.
Fig. 3.7 shows the foci produced in an infectious centre assay 
by 3 tenfold dilutions of a latently infected bone marrow.
When the infectious centre assay was being carried out the 
FeLV status of each cat involved was determined by virus isolation 
from plasma, BMSN and bone marrow culture fluids. Neither the 
latently infected or recovered cats had virus in plasma or BMSN. 
Virus was isolated from marrow culture fluids of latently infected 
cats but not from recovered cats. Plasma, BMSN and marrow culture 
fluids were all positive for the presence of virus in the viraemic 
cats.
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FIG. 3.6 Fixed cell IF on cultured bone marrow from a latently 
infected cat.
a. Demonstration of a focal area of FeLV p27 antigen 
after 8 days in culture. This preparation was 
counterstained with 0.2% carbol chromotrope in water 
in order to remove non-specific fluorescent granules 
from myeloid cells which are arrowed.
b. After 10 days in culture virtually all of the cells 
contain p27 antigen.
Magnification x 250
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TABLE 3.3
Proportion of infected cells in the bone marrow
Cat No. Status-^ No. of infectious
_________________________________________________centres per 10^ cells
21 L 36
22 L 3
23 L 60
24 L 8
25 V 1.2 x 105
26 V 6 x 103
27 V 1 x 105
28 R < 1
29 L 8
30 L 200
31 L 90
32 L 400
1 L = latently infected 
V = viraemic 
R = recovered
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FIG. 3.7 Foci produced in an infectious centre assay by 3 tenfold 
dilutions of a latently infected bone marrow. Foci are 
arrowed.
a. 4 x 10^ cells plated.
b. 4 x 103 cells plated.
c. 4 x 10^ cells plated.
The plates were stained with 1% crystal violet in 10%
formalin and 5% methanol.
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DISCUSSION
In this study the culture of aspirated bone marrow was found 
to be an efficient and reliable method of identifying latently 
infected cats. Previously Rojko et al. (1982) and Madewell and 
Jarrett (1983) had found that infectious FeLV could not be isolated 
from the BMSN of freshly aspirated marrow, but could be isolated 
from the culture fluid after cultivation of the marrow. In the 
present study bone marrow from a total of 26 latently infected cats 
were thus tested and in none of these was virus isolated from the 
BMSN. In contrast, virus was isolated from BMSN of all of 8 
viraemic cats. Upon culture of the latently infected marrow, virus 
was reactivated and isolated from the culture fluids of all 26 cats 
tested. If virus reactivation had not occurred within 4 weeks of 
culture the cat was assumed to have recovered from infection. In 
previous studies bone marrow cultures were maintained for up to 12 
weeks to find the minimum incubation period required for detecting 
reactivated virus. No culture was found to subsequently release 
virus if it were negative 3 weeks after initiation (0. Jarrett, 
personal communication). Pedersen et al. (1984) found that virus 
was reactivated within 6 to 87 days of culture. However 
reactivation occurred after 87 days in only one case and in the 
majority of cases this occurred within 6 to 21 days (N.C. Pedersen, 
personal communication). It is possible that the appearance of 
virus after 87 days was as a result of contamination from other 
cultures.
The absence of p27 in the cytoplasm or gp70 on the surface of 
uncultured latently infected cells, as determined by fixed or live 
cell IF respectively, confirmed that an active FeLV infection was 
not present. In contrast, virtually all of the nucleated cells in 
the marrow from viraemic cats contained p27, and between 1 and 10% 
of these cells were expressing gp70 on their surface.
Fixed cell IF proved to be a rapid method of detecting latency 
since after only 8 days in culture small foci of cells containing 
p27 were seen. These cells appeared to be fibroblasts and by 10
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days after the onset of culture, when a confluent monolayer had 
developed, most of the cells contained p27. However, as will be 
discussed in Chapter 6, IF is a relatively insensitive assay 
compared to the infectious centre assay described here,
Rojko et al. (1982) also used fixed cell IF to detect p27 in 
latently infected bone marrow cells after culture. These authors 
carried out the test on cells which had been resuspended and cyto- 
centrifuged rather than in situ and it is unclear how long the 
cells had been in culture before examination. However, the antigen 
was found in 20% of the cells which were identified as proliferat­
ing myelomonocytic precursor cells. Antigen was not present in 
differentiated macrophages or mature granulocytes.
Attempts have been made to reactivate latent virus from sites 
other than bone marrow (Rojko et al., 1982). Virus could not be 
reactivated from peripheral blood mononuclear leucocytes or from 
peritoneal macrophages. The only evidence to suggest that latent 
FeLV exists in extramedullary sites is that low titres of virus 
were isolated from lymph node T-cells following stimulation with 
the T-cell mitogen, staphylococcal Protein A.
An infectious centre assay was used in the present study in an 
attempt to determine the proportion of cells in the marrow which 
are latently infected. Each assay was proven to be an effective 
method of detecting infected cells since almost all of the 
chronically infected FEA/FeLV-A cells which were known to 
continuously express virus registered as infectious centres. The 
results obtained from plating bone marrow cells in these assays 
indicated that the proportion of cells in the marrow which harbour 
latent FeLV is very low, ranging from 0.0003% to 0.04%. These 
figures however may be underestimates since it is possible that not 
every infected cell will register as an infectious centre. The 
presence of latent FeLV in marrow from each of these cats was 
confirmed by virus isolation from marrow culture fluids. The fact 
that there are so few latently infected cells in the marrow may 
lead to difficulties in detection, particularly if the cat is
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beginning to recover by eliminating its latent infection (see 
Chapter 4 Discussion).
Infectious centres were not found in the bone marrow from the 
recovered cat but it is possible that the number of latently 
infected cells was below the lower limit of detection. This is 
unlikely, however, since virus was not isolated from bone marrow 
culture fluids from this cat during 4 weeks of incubation.
In contrast, between 0.6% and 12% of cells in bone marrow from 
viraemic cats registered as infectious centres. These figures 
compare well with those found by detection of gp70 on the surface 
of these cells prior to culture where between 1 and 10% of cells 
were found to be expressing antigen, and presumably virus (0. 
Jarrett; personal communication).
Although the infectious centre assay is of limited usefulness 
unless a relatively high proportion of cells carry a latent 
infection, it generally correlated well with the other methods used 
in this study to detect latency and had the great advantage of 
providing a degree of quantitation of this state.
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CHAPTER 4
PREVALENCE AND DURATION OF LATENCY 
IN A CLOSED MULTICAT HOUSEHOLD
INTRODUCTION
When a cat which is excreting FeLV is introduced into a closed 
household of susceptible cats the virus rapidly spreads to the 
other cats. The incidence of persistent viraemia in such 
households is very high. Jarrett et al. (1978a) found that 40% of 
these cats had persistent viraemia and this was confirmed in a 
later study when approximately 30% of the cats in these households 
were found to be viraemic compared to less than 1% of free range 
cats (Hardy, 1980b). The proportion of cats in these households 
which are immune, i.e. have VNAs, is also much greater than in free 
range cats. In a study carried out by Russell and Jarrett (1978b) 
42% of the cats in FeLV-infected multicat households had 
neutralising antibodies compared to only 4% of free range cats.
There are several reasons for the high incidence of infection 
in these households: cats are generally exposed to the virus at a
much younger age than free range cats; they are exposed to 
frequent and high doses of the virus, and exposure can be 
prolonged.
After the discovery of latency (Post and Warren, 1980), it was 
of interest to investigate the prevalence of this state amongst the 
ostensibly recovered immune cats in these FeLV-infected multicat 
households. Such an experimental household was initiated when 4 
persistently viraemic cats were housed with 19 16-week-old 
uninfected kittens (Madewell and Jarrett, 1983). The initial 
results of this experiment have been published (Madewell and 
Jarrett, 1983) but will be summarised here, and the events which 
took place subsequent to this publication will be described more 
fully.
It is known that recovered cats which have VNAs are resistant
to re-infection and that viraemia is life-long, therefore it was of
interest to discover the duration of the latent state and if
latently infected cats which also have VNAs were resistant to
reinfection.
6 ]
In this chapter the prevalence of latency in the multicat 
household initiated by Madewell and Jarrett (1983), and the 
duration of these latent infections is described.
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MATERIALS AND METHODS
Experimental cats
The cats used in this experiment were derived from a multicat 
household which had been established previously (Madewell and 
Jarrett, 1983). Nineteen 16-week-old uninfected kittens (cats 
1-19) were housed with 4 6-month-old cats which were excreting 
FeLV. These latter 4 donor cats became persistently viraemic 3 
weeks after receiving an intraperitoneal inoculation of 1.8 x 10^ 
fiu of FeLV-A/Glasgow-1 at 8 weeks of age.
At intervals of 4 months after the onset of continuous 
exposure to the donor cats blood and bone marrow samples were 
obtained from cats 1-19 to test for evidence of FeLV infection. 
Monitoring continued over a period of 3 years. The present author 
was responsible for this experiment from 64 weeks after exposure to 
the donor cats. By this time the donor cats had been removed from 
the house.
RESULTS
Prevalence of latency
Blood and bone marrow samples were taken from the cats at the 
times indicated in Table 4.1. Plasma samples were tested for the 
presence of FeLV antigen by ELISA and infectious virus by virus 
isolation. Serum was tested for VNAs and anti-FOCMA antibody. 
Bone marrow cultures in duplicate were maintained for 4 weeks and 
tested for the presence of reactivated virus at weekly intervals as 
described in Chapter 3. The results are given in Table 4.1.
Thirty-six weeks after initial exposure to the 4 donor cats, 
the 19 cats could be divided into 3 distinct groups.
The cats in the first group (cats 1-3) were persistently 
viraemic. FeLV antigen was demonstrated in their plasma by ELISA 
and infectious virus was isolated. Infectious virus was also 
detected in the bone marrow collecting medium prior to culture, and 
in the medium after culture. These cats did not develop VNAs 
although cat 2 had low levels of anti-FOCMA antibodies.
In the second group (cats 4-12) infectious virus was not 
isolated from plasma although cat 4 had detectable antigen. Bone 
marrow collecting medium from these cats did not contain infectious 
virus, but virus was detected in the medium after the marrow had 
been in culture. These cats were said to be latently infected. All 
had VNAs and anti-FOCMA antibodies.
The third group consisted of cats 13-19. Neither viral 
antigen nor infectious virus was demonstrated in their plasma. 
Infectious virus was not detected in bone marrow collecting medium, 
or in medium after the marrow was cultured. Like the second group 
of cats, these cats all had VNAs and anti-FOCMA antibodies and were 
therefore believed to have recovered from infection.
TABLE 4.1 Latency in cats following contact exposure to FeLV
Cat
No. E V
36*
B VNA F E V
64
B VNA F E V
88
B
Weeks
VNA
after
F
exposure 
110 
E V B VNA F E V
138
B VNA F E V
160
B VNA F
Cat
No.
1 + + + 0 0 + + + 0 0 Dead 1
2 + + + 0 16 + + + 0 2 + + + 0 0 + + + 0 2 + + + 0 2
3 + + + 0 0 + + + 0 2 + + + 0 0 + + + 0 2 + + + 0 3
4 + - + 8 64 - - + 8 8 - - + 2 4 - - + 8 8 + - + 4 16 + + 4- 0 4
5 - - + 32 256 - - - 32 32 - - - 32 64 - - + 64 64 - - + 16 128 - - - 32 16 5
6 - - + 64 32 - - - 16 32 - - - 64 64 - - - 64 64 - - - 8 32 - - - 16 32 6
7 - - + 128 64 - - - 128 32 - - - 64 16 - - - 64 128 - - - 16 64 - - - 0 128 7
8 - - + 64 128 - - + 16 32 - - + 64 16 - - + 64 32 - - 16 256 - - + 64 64 8
9 - - + 8 32 - - + 32 64 - - + 64 64 - - + 64 64 Dead 9
10 - - + 32 8 - - - 16 16 - - + 64 8 - - - 32 32 - - - 8 64 - - - 32 32 10
11 - - + 64 16 - - - 32 64 - - - 64 128 - - - 64 128 - - - 16 256 - - - 64 32 11
12 - - + 128 128 - - + 32 128 - - - 64 64 - - - 64 128 - - - 8 64 - - - 64 32 12
13 - - - 64 16 ■- - - 32 16 Dead 13
14 - - 8 16 - - - 8 8 - - + 16 4 - - - 16 64 - - 8 16 - - - 16 8 14
15 - - - 8 8 - - - 4 4 - - - 8 8 - -  . - 2 16 - - - 4 16 - - - 2 8 15
16 - - - 64 4 - - - 64 32 - - + 64 8 - - 64 64 - - 8 256 - 64 64 16
17 - - - 32 16 - - - 64 8 - - - 64 16 - - 64 32 - - - 16 32 - - - 16 64 17
18 - - - 16 32 - - - 16 32 - - - 32 32 - - - 64 32 - - - 16 64 - 32 16 18
19 2 2 — 8 8 — — — 2 2 — — — 4 32 - - - 2 4 — — — 4 2 19
E = ELISA antigen in blood.
V = Virus isolation from blood
B = Virus isolation from bone marrow culture
+ = Virus isolated
- = Virus not isolated
VNA = Virus neutralising antibody titre
F = Anti-FOCMA antibody titre
Where no result is given the test was not done.
* Results from Madewell and Jarrett (1983).
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The blood samples taken at 64, 88 and 110 weeks after initial 
exposure showed that the VNA and anti-FOCMA antibody titres for 
each cat remained very stable. At around 110 weeks several of the 
latently infected and recovered cats were rehoused for the purposes 
of breeding in order to determine whether or not any transmission 
of FeLV occurred between latently infected cats and their kittens. 
Details of this experiment are given in Chapter 5. The viraemic 
cats (cats 2 and 3) were also removed from the multicat household 
at this time and rehoused together. During the interval between 
rehousing and the next sampling at 138 weeks there was a fourfold 
decrease in the cats' VNA titres. Serum samples taken at 160 weeks 
after exposure showed a slight increase in VNA titres.
Duration of latency
The proportion of cats which were not viraemic, i.e. were 
ostensibly recovered, but which had latent infections in their 
marrow was initially high (56% at 36 weeks after infection). It 
was found, however, that with time this proportion decreased with 
the exception of the 88 week sampling when there was a transient 
increase in the proportion of cats with latent infections. Those 
cats which no longer had detectable virus in their marrow had 
recovered from infection. After 160 weeks only 1 of the 
non-viraemic cats (cat 8) had a latent infection (8%). This cat 
was still latently infected after 210 weeks. The figures are shown 
in Table 4.2 and are given as the percentage of the non-viraemic 
cats still alive at each sampling which had latent infections at 
the times indicated.
These results show that the latent state is relatively 
short-lived with few infections lasting longer than 2.5 years.
Cat 4, which was one of the latently infected queens used in 
the breeding experiments mentioned above, was intermittently 
positive by ELISA for the presence of FeLV antigen. At 160 weeks 
she reactivated her latent infection and became persistently 
viraemic. At this time her VNA levels, which had always been low, 
had dropped to 0. This cat will be discussed in detail in Chapter 
5.
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TABLE 4.2
Proportion of cats with latent infections 
at intervals following exposure
Cats with latent infection 
Weeks after exposure__________Proportion^_______ Percent
0 0/19 0
36 9/16 56
64 4/16 25
88 6/15 40
110 4/15 27
138 2/14 14
160 1/13 8
210 1/13 8
1 The proportion of non-viraemic cats still alive at each sampling 
which had latent infections.
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Three of the cats died during the course of the experiment. 
Cat 1 was persistently viraemic and developed ulcerative colitis 
and died between 64 and 88 weeks after exposure. Cat 9 was 
latently infected and died between 110 and 138 weeks after exposure 
as a result of a perforated pyometra. The third cat (cat 13) was 
recovered and died as a result of a blocked urethra between 64 and 
88 weeks after exposure.
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DISCUSSION
The cats in the multicat household described here were 
infected by the horizontal transmission of virus as occurs in the 
field.
Thirty-six weeks after exposure to the donor cats 3 out of the 
19 cats were persistently viraemic. This represents a very low 
proportion, only 15%, compared to that observed in other multicat 
households in the field which have been studied where the 
proportion was 30-40% (Jarrett et al., 1978a; Hardy, 1980b). A 
probable reason for the low incidence of viraemia in the present 
study is that the cats were 16 weeks old when first exposed to the 
virus and had therefore developed an age resistance to the 
infection (Hoover et al. , 1976), compared to the situation in the 
field where kittens are born into these households and exposed to 
the virus at a very early age.
The 3 viraemic cats did not make VNAs therefore did not have a 
protective immune response. However, anti-FOCMA antibodies which 
are believed by some authors to protect against tumour development 
(Essex et al. , 1971a) were detected in two of these cats. The 16 
remaining cats in the house had all been infected with the virus by 
36 weeks from initial exposure since they all had anti-FOCMA 
antibodies. These cats were also immune as determined by the 
presence of VNAs in their sera.
At this time virus could be reactivated from the bone marrow 
of 9 of the 16 cats (56%). These 9 cats were therefore assumed to 
have latent infections. The remaining 7 cats were believed to have 
recovered since virus could not be isolated from their cultured 
marrow. As time went on, the proportion of latently infected cats 
decreased, with the greatest decrease occurring between 36 and 64 
weeks after exposure. Pedersen et al. (1984) also found that the 
proportion of cats with latent infections decreased with time but 
in this latter study the greatest decrease occurred after 28
weeks. In the present study after 160 weeks only 8% of the immune
cats still had latent infections.
Those cats which no longer had reactivatable virus in their 
marrow were thought to have recovered. The fact that there was an 
increase in the proportion of latent infections at 88 weeks after 
exposure may be indicative of a sampling error on the previous 
occasion because, as discussed in Chapter 3, the use of the 
infectious centre assay showed that very few cells in the marrow 
contain latent virus. It may therefore be possible to obtain an
aspirate which does not contain any infected cells.
The factors responsible for eliminating a latent infection 
resulting in recovery are as yet unknown. Rojko et al. (1982) 
found that latent virus was present in immature but not 
differentiated myeloid cells. It is possible, therefore, that 
latency ends when infected precursor cells have differentiated to 
maturity. The more primitive the infected cells are and the 
greater their numbers, the longer the latent infection might last. 
If this were the case, then one possibility is that in those cats 
which have a long-term latent infection the virus is present either 
in myeloid stem cells or in longer-lived cells such as lymphocytes.
It is also possible that an immune mechanism is responsible 
for eliminating latent infections. For instance, neutralising 
antibody, which is present in all latently infected cats, may kill 
any virus which is expressed or may kill those cells which express 
it. Similarly, cytotoxic T-cells may have a role. Latency may 
therefore end when all of these cells have been killed. The 
possible factors which control latency are discussed in Chapter 6.
In the present study all of the latently infected and 
recovered cats were resistant to reinfection from the viraemic 
cats. Their antibody levels remained stable throughout the 
experiment with the exception of a fourfold decrease in their VNA 
titres observed between 110 and 138 weeks. This may be due to the 
removal of the viraemic cats and therefore the removal of the
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challenge at this time. The VNA titres tended to increase again at 
160 weeks and so the variation observed could merely indicate 
individual assay variation.
The only exception was cat 4 which spontaneously reactivated 
her latent infection to become persistently viraemic. This cat had 
been intermittently antigenaemic, had had very low levels of VNAs 
and may always have been on the verge of viraemia. She became 
viraemic after being exposed to several litters of viraemic kittens 
and she will be discussed in more detail in Chapter 5.
In summary, the prevalence of latent FeLV infections in 
multicat households can be very high following the introduction of 
viraemic cats. In view of these results it is likely that a large 
proportion of the cats in the extensive study carried out by 
McClelland et al. (1980) had latent infections. However, latency 
is usually short-lived with approximately 10% of the infections 
lasting more than 3 years, and the cats are generally immune and 
resistant to reinfection upon continuing exposure to the virus.
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CHAPTER 5
CLINICAL AND EPIDEMIOLOGICAL 
SIGNIFICANCE OF LATENCY
INTRODUCTION
Cats which are persistently viraemic with FeLV are at risk of 
developing a number of diseases associated with the virus (see 
Chapter 1, Section 2). In a prospective study of cats exposed to 
FeLV McClelland et al. (1980) found that 83% of the viraemic cats 
in multicat households were dead within 3.5 years compared to only 
17% of cats in uninfected households. Cats which had been exposed 
to the virus but which had developed a protective antibody 
response, and were therefore immune, were no more at risk of 
developing FeLV-associated disease than unexposed cats.
As discussed in the previous Chapter, a considerable 
proportion of the non-viraemic cats in a FeLV-infected multicat 
household may harbour latent infections. In this Chapter the 
results of experiments to assess the clinical and epidemiological 
significance of latency are described. Initially the following four 
questions were posed. First, are latently infected cats suscept­
ible to any of the FeLV-associated diseases? Secondly, can these 
cats spontaneously reactivate virus to become viraemic? Thirdly, 
is there horizontal transmission of virus from latently infected to 
susceptible cats? Fourthly, do latently infected queens transmit 
infection to their kittens, either before or after birth?
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MATERIALS AND METHODS
Horizontal transmission
Eight 4-month-old uninfected kittens (cats 33-40) were used as 
tracer cats and were housed together with 8 latently infected cats 
(cats 41-48) to determine whether or not FeLV was horizontally
transmitted from latently infected cats.
a) Source of latently infected cats
The latently infected cats developed their infections in a
variety of ways as summarised in Table 2.1. Cats 41 and 42 became 
infected after receiving an oronasal dose of 1 x 10^ fiu of 
FeLV-A/Glasgow-1 in 1 ml Leibovitz L-15 medium at 16 weeks of age. 
Cats 43, 44 and 45 were inoculated with an experimental FeLV
vaccine and challenged as described in Chapter 3. These cats
resisted viraemia but became latently infected. Cats 46, 47 and 48 
were unvaccinated control cats which had been challenged oronasally 
with 1 x 10^ fiu of FeLV-A/Glasgow-1 in 1 ml Leibovitz L-15 medium 
at 14 weeks of age.
Congenital transmission
a) Source of cats
The latently infected and recovered cats in the multicat 
household described in Chapter 4 were studied for the possible 
transmission of infection to their kittens either before or after 
birth. In addition, a tom cat (cat 20) which became latently 
infected after receiving an intraperitoneal dose of 8 x 10^ fiu of 
FeLV-A/Glasgow-1 in 1 ml Leibovitz L-15 medium at 9 weeks of age, 
was used.
b) Collection of bone marrow from newborn kittens
Newborn kittens were anaesthetised by enclosing them in a 
small perspex box containing a pad of cotton wool which had been
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soaked in halothane (Fluothane, ICI). The fur was clipped and the 
gluteal area was disinfected as described in Chapter 3. Femoral 
bone marrow aspirates were taken using a 21 gauge needle and a 5 ml 
syringe. The marrow was taken into collection medium and cultured 
as described in Chapter 3.
c) Collection of milk
Mild sedation of the cat was achieved by giving 10 mg/kg 
ketamine hydrochloride by intramuscular injection. A volume of 0.3 
ml of oxytocin-S (Intervet) was also given intramuscularly to aid 
the collection of milk. The fur around the mammary glands was 
closely clipped and the skin was disinfected with 0.5% Hibitane and 
allowed to dry. Milk was then manually expressed and approximately 
1 ml was collected into a sterile 10 ml plastic centrifuge tube.
d) Preparation of milk for virus isolation
The milk was diluted to 3 ml in Leibovitz L-15 medium and was 
centrifuged at 2000 rpm for 10 minutes to pellet the cells. The 
supernatant was then collected and passed through a 0.45 pm filter 
and was stored at -70°C in aliquots of 1 ml prior to being tested 
for the presence of FeLV.
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RESULTS
Clinical significance of latency
The incidence of ill-health in cats which had had latent FeLV 
infections for up to 4 years was very low. Table 5.1 lists all of 
the latently infected cats which were studied, giving the duration 
of study and medical history. Only one cat in the multicat 
household, cat 9 became ill. She developed a pyometra and 
subsequently died.
Epidemiological significance of latency
a) Horizontal transmission
Blood and bone marrow samples were taken from the tracer cats 
before the start of the experiment. The cats were all free from 
antigenaemia, viraemia and latent infection and none of those which 
were tested had VNAs. Serum samples taken from the latently 
infected cats prior to the start of the experiment were positive 
for the presence of VNAs.
At intervals of 14 to 16 weeks blood and bone marrow samples 
were taken from all 16 cats. Plasma was tested for the presence of 
FeLV antigen and infectious virus, and bone marrow was cultured in 
order to detect latent infections. Serum was tested for the 
presence of VNAs. The results are given in Table 5.2.
None of the tracer cats developed latent or active infection 
with FeLV and none developed neutralising antibodies to the virus.
Cats 41-48 had detectable VNAs throughout the experiment. 
However at the 54 week sampling 2 of these cats (cats 44 and 48) 
had eliminated their latent infections.
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TABLE 5.1
Medical history of latently infected cats
Cat No. Duration of study Medical history
______________________  (months)__________________________________
4 36 Healthy
5 36 "
6 36 ti
7 36 •
8 48 V I
9 24 Pyometra: died
10 36 Healthy
11 36 VI
12 36 V I
20 36 ••
21 9 V I
22 9 I I
23 9 • I
24 9 II
29 24 I I
30 24 II
31 24 I I
32 24 II
41 18 • 1
42 18 I I
43 18 II
44 18 I V
45 18 • V
46 18 V I
47 18 v v
48 18 vv
TABLE 5.2 Attempts to demonstrate horizontal transmission
of FeLV from cats with latent infections
Weeks after exposure
Cat
No.
Pre-contact 
E V B VNA E V
14
B VNA E V
30
B VNA E V B
43
VNA E V
54
B ■ V M
Tracer cats
33 - - - - 0 - - - 0 - - 0 - - - 0
34 _ 0 - - - 0 - - 0 - - - 0 - - - 0
35 - - - - 0 - - - 0 - - - 0 - - - 0
36 _ 0 - - - 0 - - - 0 - - - 0 - - - 0
37 _ - - - 0 - - 0 - - - 0 - - - 0
38 - - - - 0 - - 0 - - - 0 - - - 0
39 - - - 0 - - - 0 - - 0 - - - 0 - - - 0
40 _ - - . - 0 - - 0 - - - 0 - - - 0
Latently infected cats
41 - - + 64 - - + 64 - - + 32 - + 512 - - + 32
42 + 128 - - + 64 - + 64 - - + 128 - - + 32
43 + - + 64 tr - + 32 tr - + 512 tr - + 32
44 + 2048 - - + 1024 - - + 64 - + 2048 - - - 512
45 + 2048 - - + 1024 - + 128 - - + 128 - - + 512
46 + 4 - - + 32 - + 64 - - + 512 - - + 1024
47 + 256 - - + 8 - - + 4 - + 16 - - + 8
48 - - + 128 - - + 32 - - 8 - - + 2 - - - 8
E = ELISA antigen in blood.
V = Virus isolation from blood
B = Virus isolation from bone marrow culture
+ = Virus isolated
- = Virus not isolated
VNA = Virus neutralising antibody titre
tr = trace of colour in ELISA
Where no result is given the test was not done
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b) Congenital transmission
i) First litters
Eight queens in the multicat household detailed in Chapter 4 
gave birth to their first litters between 64 and 8 8 weeks after 
initial exposure to FeLV. Of these, 5 had latent infections at
that time (cats 4, 8 , 10, 14 and 16) and 3 had recovered from
infection (cats 12, 18 and 19). At parturition blood samples were
taken from the mothers to test for the presence of viral antigen
and infectious virus, and two kittens from each litter were 
sacrificed. Blood samples from these kittens were also tested for 
the presence of viral antigen and infectious virus and their bone 
marrow was cultured to determine whether or not congenital latent 
infections were present. None of the mothers or kittens tested had 
antigen or virus in their plasma. The kittens were therefore 
believed to be free from congenital active infection.
The bone marrow cultures from these kittens were grown for at 
least 4 weeks, with the exception of those from the kittens of cat 
4 which became contaminated with bacteria at an early stage. All 
of the cultures were tested at weekly intervals for the presence of 
reactivated virus and were found to be negative.
Blood samples which were taken from the remaining kittens of 
each litter at 12 weeks of age showed that one of the kittens of 
cat 4 became viraemic.
ii) Second litters
In the light of these results cat 4 and another latently 
infected queen (cat 8 ) which was chosen at random from the other 
queens, were removed from the multicat household and rehoused 
together with 3 tom cats. Two of these toms, cats 5 and 6 , were 
from the multicat household and had recovered from infection and 
the third, cat 2 0 , was latently infected.
Four kittens were born to each of the queens and they were 
reared together in the presence of the toms. The first blood and 
bone marrow samples were not taken until the kittens of cat 4 (4B1 
- 4B4) were 15 weeks of age and those of cat 8 (8B1 - 8B4) were 18 
weeks of age. It is therefore not known if congenital active or 
latent infections were present in these kittens.
By the time of first sampling 4 kittens (4B1, 4B2, 4B3 and 
8B1) were viraemic and one (8B2) was antigenaemic. Two of the 
kittens (4B4 and 8B2) had virus in their bone marrow but not in 
their blood. The results are shown in Table 5.3. Blood samples 
were taken from the kittens over the following 5-6 weeks. There 
was little change in their virus status. Kittens 4B4 and 8B2 
remained free from viraemia with 8B2 eliminating its antigenaemia; 
kitten 8B4 remained completely free from antigenaemia and 
viraemia. At 22 weeks of age kitten 8B3 who had been free from 
infection until that time became antigenaemic.
Serum samples which were taken at each bleeding were tested 
for the presence of VNAs and anti-FOCMA antibodies. The results 
are shown in Table 5.3. The only kittens to develop VNAs were 4B4 
and 8B2, and all eventually developed anti-FOCMA antibodies.
Blood samples were taken at regular intervals from the adults 
and at no time was viraemia detected in any of them. Cat 4, 
however, was intermittently antigenaemic. At the time of last 
bleeding oropharyngeal swabs were taken. None of the adults had 
infectious virus in the saliva. VNA and anti-FOCMA antibody titres 
remained constant over the course of the experiment. The results 
are given in Table 5.3.
iii) Third litters
Approximately one week prior to kittening cats 4 and 8 were 
removed from the tom cats and rehoused in individual huts so that 
their litters could be reared in isolation from each other. Within 
the first seven days of life blood and bone marrow samples were
TABLE 5.3 Transmission of FeLV to kittens of queens with latent infections
Age of kittens in weeks 
Cat 15 18 20 22
No. E V B VNA F E V B VNA F E V VNA F E V B VNA F M
4B1 + + + 0 32 + + 0 8 + + 0 8
4B2 + + + 0 •32 + + 0 16 + + 0 128
4B3 + + + 0 16 + + 0 0 + + 0 4
4B4 - - + 32 32 - - 8 16 - - 16 128
8B1 + + + 16 + + 0 256 + + 0 128
8 B2 + - + 64 - - 16 256 - - 8 128
8B3 - - - 0 - - 0 0 + - 0 64
8B4 - - - 0 - - 0 0 - - 0 16
4 + - 4 4 tr — 4 2 - - + 4 16 -
8 - - >64 16 - - 32 32 - - + 32 32 -
5 - - >64 32 - - 32 64 - - - 16 16 -
6 - - >64 16 - - 32 32 - - - 32 32 -
20 — 64 16 — — 32 32 “ — + 16 32
E = ELISA antigen in blood.
V = Virus isolation from blood
B = Virus isolation from bone marrow culture
+ = Virus isolated
- = Virus not isolated
VNA = Virus neutralising antibody titre
F = Anti-FOCMA antibody titre
M = Virus isolated from mouth
tr = trace of colour on ELISA
Where no result is given the test was not done
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taken from the kittens. None of the kittens had antigenaemia,
viraemia or latent infection at that time but VNAs and anti-FOCMA 
antibodies were detected in their blood. Blood samples and
oropharyngeal swabs were taken from the kittens twice weekly and 
from the queens once weekly. Second bone marrow biopsies were
taken when the kittens were 7 weeks old. The results are shown in 
Table 5.4.
By 8 weeks of age 2 of 3 of the kittens of cat 4 (4C2 and 4C3) 
had developed antigenaemia and viraemia and the third (4C1) had 
detectable virus in its bone marrow. At this time VNAs could no
longer be detected in the serum of these kittens although they
still had anti-FOCMA antibodies. Two weeks later kitten 4C1 became 
viraemic. Infectious virus could not, however, be isolated from
the saliva of these kittens. Although cat 4 was again inter­
mittently antigenaemic she was never viraemic and virus could not 
be isolated from her saliva.
The kittens of cat 8 remained completely free from anti­
genaemia, viraemia, and latent infection. VNAs could be detected 
in their sera until they were 8 weeks old and anti-FOCMA antibodies 
were detected throughout the experiment.
iv) Fourth litter
An uninfected tom cat (cat 49) was housed with cat 4 and sired 
her fourth litter. He remained in the house during her subsequent 
pregnancy and lactation. Blood samples were obtained from the 
kittens (4D1 - 4D3) prior to suckling and they were all found to be 
negative for viral antigen and infectious virus. A 12-day-old 
kitten (4D4) from an uninfected queen (cat 60) was fostered on cat 
4 when this litter was born. Blood samples were taken weekly and 
oropharyngeal swabs were taken on alternate days from mother and 
kittens. Bone marrow biopsies were obtained when kittens 4D1, 4D2 
and 4D3 were 7 days and 45 days old.
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TABLE 5.4 Transmission of FeLV to isolated litters
of queens with latent infections
Age of kittens (weeks)
Cat
No.
Pre-kittening 
E V B VNA F M
0
E V B E V
4
VNA F M E V B
8
VNA F M E V
12
VNA F M
4 - - + 4 16 - + 8 32 + 4 32
4C1 - - - - 4 8 - - - + 0 8 - + + 0 256 -
4C2 - - - - 8 8 - + + + 0 32 - + + 0 4 -
4C3 - - - - 8 8 - + + + 0 4 - ■ + + 0 32 -
8 - - + 64 32 - - - 16 64 - - - 32 64 - - - 32 64 -
8C1 - - - - 16 8 - - - - 4 8 - - - 0 4 -
8C2 - - - - 2 4 - - - - 0 4 - - - 0 8 -
8C3 - - - 4 8 - - - - 2 8 - - - 0 32 -
8C4 — — 4 16 — — — - 8 8 — — — 0 4 —
E = ELISA antigen in blood.
V = Virus isolation from blood
B = Virus isolation from bone marrow culture
+ = Virus isolated
- = Virus not isolated
VNA = Virus neutralising antibody titre
F = Anti-FOCMA antibody titre
M = Virus isolated from mouth
Where no result is given the test was not done.
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The results from sampling this litter are summarised in Table 
5,5. There was no evidence of congenital active or latent 
infection in any of the kittens. At one week of age the kittens of 
cat 4 had detectable VNAs and anti-FOCMA antibodies whereas her 
foster kitten had not. This latter kitten developed viraemia 
within 3 weeks of fostering, but kittens 4D1 - 4D3 did not become 
viraemic until 6 weeks of age. By this time kittens, 4D1, 4D2 and 
4D3 had no detectable VNAs, and kitten 4D4 had developed anti-FOCMA 
antibodies. FeLV was isolated from the saliva of the viraemic 
kittens.
Infectious virus was not detected in the blood or saliva of 
cat 4 at any time. Two milk samples were taken from her when her 
kittens were 42 and 52 days old. Infectious virus was isolated 
from both of these.
After the kittens were removed from the house, blood samples 
and oropharyngeal swabs were taken regularly from cat 4. It was 
found that cat 4 spontaneously reactivated her latent infection to 
become persistently viraemic 1 1 weeks after kittening.
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TABLE 5.5 Transmission of FeLV from latently 
infected queen to a fostered kitten
Cat
No.
0
E V
1
E V B VNA F M E
Age of 
3
V VNA
kittens 
F M
(weeks) 
E V B
6
VNA F M E V
8
VNA F M
4 + 2 16 + 2 32
4D1 - -  »  _ 4 8 - - , 2 0 - + + + 0 0 + + + 0 64 ! +
4D2 - _  _  _  4 16 - - 0 4 - + + + 0 4 - + + 0 128 |
4D3 - - 2 16 - - 2 - + + + 0 4 + + + 0 128 I +
4D4 -  0 0 - + + 0 0 + + + + 0 8 + + + : oj 128 +
E = ELISA antigen in blood.
V = Virus isolation from blood
B = Virus isolation from bone marrow culture
+ = Virus isolated
- = Virus not isolated
VNA = Virus neutralising antibody titre
F = Anti-FOCMA antibody titre
M = Virus isolated from mouth
Where no result is given the test was not done.
DISCUSSION
In this study 26 latently infected cats were studied for 
periods ranging from 9 months to 4 years. None developed any of 
the diseases commonly associated with FeLV, although one, cat 9, 
died of an unrelated cause. This figure represents only 4% and is 
in sharp contrast to the situation with persistently viraemic cats, 
where 83% were dead within 3.5 years of natural exposure to 
infectious FeLV (McClelland et al., 1980). From the present 
results it is clear that a significant proportion of the cats in 
that study which were believed to have "recovered" from infection 
with FeLV must have had latent infections, but only 50 out of 321 
(16%) died during the 3.5 year period. Similarly, Pedersen et al. 
(1984) found that only 12% of FeLV "recovered" cats developed 
disease over periods ranging from 6 months to 6 years. Again, a 
proportion of these cats presumably had latent infections. Cats 
with latent FeLV infections therefore do not appear to be at risk 
of developing FeLV-associated diseases.
Since there is epidemiological evidence that some of the 
non-viraemic cats with lymphosarcoma have had previous exposure to 
FeLV (Hardy et al., 1980), the possibility of latent FeLV infection 
being involved in such cases has been considered. Rojko et al.
(1982) found that latent virus was reactivated from cultured bone
marrow cells, but not from blood or tumour cells, from 2 
FeLV-negative lymphosarcoma cases. This is in contrast to the 
results of Madewell and Jarrett (1983) who were unable to 
demonstrate latent FeLV in bone marrow cells of 2 FeLV-negative 
cats with lymphosarcoma or myeloid leukaemia. The possible role of 
latent FeLV in virus-negative lymphosarcomas is therefore
unresolved.
Cats which are persistently viraemic with FeLV transmit the 
infection horizontally to susceptible cats through virus-containing 
saliva (Hardy et ai., 1973a). The possibility of horizontal
transmission of FeLV from latently infected cats was studied in an
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experiment in which susceptible tracer cats were housed together 
with cats known to have latent infections.
During one year of exposure there was no evidence of 
horizontal transmission of virus from the latently infected to the 
tracer cats. None of the tracer cats developed active or latent 
infections or VNAs. All of the latently infected cats maintained 
VNA titres and none spontaneously reactivated its infection to 
become viraemic. Indeed, by the end of the experiment only 6 of 
these cats were still latently infected, the other 2 (cats 44 and 
48) having eliminated their infections. This is in contrast to the 
situation with viraemic cats where there is evidence of horizontal 
transmission to susceptible cats within one month of exposure 
(Jarrett et al., 1973b).
From the results of this study it appears that, unlike 
persistently viraemic cats, latently infected cats do not 
horizontally transmit FeLV infection. This conclusion agrees with 
the preliminary findings of Madewell and Jarrett (1983) that there 
was no transmission of infection from one latently infected cat 
(cat 2 0 in the present study) to 6 susceptible kittens during 8 
months of observation.
Although the tracer cats used in this experiment were not as 
susceptible as kittens under 8 weeks of age to developing 
persistent viraemia, they would, however, be susceptible to 
infection and would therefore be expected to seroconvert and become 
immune if transmission of infection had occurred from the latently 
infected cats. In order to find whether these cats would develop 
VNAs when challenged with the virus, they have now been housed with 
three persistently viraemic cats. This experiment is in progress 
and will not be included in this thesis.
The other major mode of transmission of FeLV is by the 
infection in utero of foetuses of persistently viraemic queens. 
All kittens born to such queens are themselves persistently 
viraemic (Jarrett and Russell, 1978). Eight latently infected
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queens were therefore studied for the possible transmission of 
infection to their kittens either before or after birth.
From the results of the study of the first litters it was 
clear that none of the kittens which were sacrificed at birth had 
acquired a congenital viraemia. Although it is impossible to 
determine whether or not the kittens of cat 4 were harbouring 
congenital latent infections, it is known by the absence of 
reactivated virus in the bone marrow cultures from the sacrificed 
kittens of other litters that they were all free from congenital
latent infection. By 12 weeks of age one of the remaining kittens
of cat 4 was persistently viraemic although the source of its 
infection was not established.
The second litters from cats 4 and 8 confirmed the trans­
mission of virus to the kittens of both litters since by the time 
of first sampling 4 of the 8 kittens were viraemic and another 2 
were latently infected. The source of the infection was still
unidentified and it is unknown whether or not congenital infections 
had occurred.
As expected, none of the viraemic kittens had VNAs while the 2 
latently infected kittens had antibodies. It is likely that these 
antibodies were actively acquired after exposure to the virus since 
passively acquired colostral antibody which has a half-life of 9.5 
to 15 days (Scott et al., 1970; Jarrett et al., 1977) would have 
disappeared by that time. Interestingly, an antibody response was 
not detected in kittens 8B3 or 8B4 until 23 weeks of age when they 
were found to have anti-FOCMA antibodies indicating exposure to 
FeLV. It is possible that the comparatively late exposure of these 
kittens to the virus was due to a lack of socialising since 
intimate contact between cats is necessary for the transmission of 
infection (Hoover et al. , 1977a).
Although infectious virus was not detected in the blood or 
saliva of any of the adults, cat 4 was found to be intermittently 
antigenaemic. Therefore it seemed likely that this cat was the 
source of the infection.
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The results of studying the third litters of cats 4 and 8 , 
which were reared in isolation from each other, showed that 
congenital infection was not present in any of the kittens and
confirmed the belief that cat 4 was the source of infection since
her kittens became viraemic between 7 and 8 weeks after birth. By 
this time colostral antibodies could not be detected. The fact 
that virus was not isolated from the saliva of these kittens 
possibly represents a sampling error. The kittens of cat 8 , 
however, remained free from active or latent infection even after 
their colostral VNA levels had dropped to undetectable levels. 
This result suggested that in the previous litter, these kittens 
had been infected by horizontal spread of virus from the kittens of 
cat 4.
Again, cat 4 had not been viraemic but had been antigenaemic 
and it appeared that she infected her kittens post-natally although 
it was still unknown how the infection occurred.
It was believed that passively acquired colostral VNAs
protected the kittens of cat 4 from viraemia at an earlier age.
Therefore when her next litter, which was sired by an uninfected 
tom cat (cat 49), was born, a 12-day-old normal kitten (4D4) was 
fostered on her. Since this kitten had no passively acquired FeLV 
antibodies from its own mother, and by 12 days of age would no 
longer be capable of absorbing antibody from the colostrum of cat 
4 (Brambell, 1970), it would be fully susceptible to FeLV. In fact 
this kitten became viraemic within 3 weeks of fostering while cat 
4's own kittens (4D1-4D3) did not become viraemic until 6 weeks of 
age when again the occurrence of viraemia coincided with the 
disappearance of passively acquired VNAs from the sera of the 
kittens. Thus the protective effect of these antibodies in the 
first few weeks of life was confirmed.
It may be significant that cat 4 differed from the other 
latently infected cats in the study in two ways: firstly she was
intermittently antigenaemic, and secondly, she had low levels of 
VNAs. These may be predisposing factors for the transmission of 
infection from latently infected cats.
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The source of the infection was found to be the milk of cat 4 
since infectious virus was isolated from 2 samples taken at 42 and 
52 days post-partum. Although FeLV has previously been demon­
strated in the milk of viraemic cats (Hardy et al., 1976a) this is 
the first demonstration of virus in the milk of a latently infected 
cat. It is possible therefore that cats which are antigenaemic and 
not detectably viraemic but which have latent infections actually 
produce infectious virus at extramedullary sites such as the 
mammary gland. Approximately 10% of cats which are antigenaemic 
are not viraemic (Jarrett et al., 1982) and it is possible that 
some of these have latent infections. Cats like these could 
complicate the control and eradication of FeLV from multicat 
households and could explain the reappearance of viraemic cats 
which has been reported in such households after long periods 
without overt infection (Rojko et al. , 1982; 0. Jarrett, personal 
communication).
In what may be a similar situation Lutz et al. (1980) isolated 
FeLV in cultures of the foetal cat cell line (fcwf-4) inoculated 
with the ultracentrifuged pellet of urine from an antigenaemic, but 
non-viraemic cat. However virus was not isolated from cultures of 
fcwf-4 cells which had been exposed to bone marrow from this cat 
although it is not recorded for how long the bone marrow was 
cultured. This cat therefore may or may not have had a latent bone 
marrow infection.
It is clear from the results of the present study that 
congenital transmission of infection from latently infected cats 
did not occur since none of the kittens had active or latent 
infections at birth. By contrast, Rojko et al. (1982) found 
evidence of congenital latent infections in kittens born to 2 
latently infected queens. However that study is flawed since the 
queens had been re-exposed to FeLV by receiving an intraperitoneal 
inoculation of virus during the first week of gestation. It is 
therefore impossible to know if the congenital infection in the 
kittens was a result of true transmission from their mothers, or 
was a consequence of the virus given to the mothers during 
pregnancy.
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Pedersen et al. (1984) have also studied the possible 
transmission of infection from latently infected queens to their 
kittens. Twenty-nine of 30 kittens had no evidence of congenital 
infection. The remaining kitten, which was one of a litter of 3, 
was claimed to be viraemic at birth, although the first blood 
samples were not obtained until the kittens were 2 weeks of age. 
The litter-mates of this kitten then became infected at 10-13 weeks 
of age by what was believed to be the horizontal transmission of 
virus from the viraemic kitten. It is possible that these kittens 
like those of cat 4, were protected from viraemia at an earlier age 
by maternally derived antibody, although this is not known since 
antibody titres were not investigated. The mother of these kittens 
(cat P) was never antigenaemic, and presumably not viraemic, during 
pregnancy of lactation. Interpretation of these results poses 
problems because if like cat 4, cat P was producing infectious 
virus at an extramedullary site such as the uterus it is difficult 
to explain why infection was transmitted to only one of 3 
foetuses. If only small amounts of virus were being produced in the 
uterus which were undetectable in the blood of the mother the 
probability of infection may have been such that only one foetus in 
the litter became infected. The fact that each foetus in the cat 
has a separate blood supply and that these blood supplies are not 
interconnected may then explain why the infection did not spread 
from foetus to foetus.
Alternatively the situation which occurred with this queen 
could be similar to that in avian leukosis virus infections where 
only a proportion of the embryos in the eggs of hens which are 
viraemic but which also have antibodies become infected (Spencer _et 
al. , 1977; Payne et al., 1982). Those embryos which do not become 
infected are believed to be protected by maternal antibody in the 
yolk. If cat P produced very small amounts of virus locally in the 
uterus or placenta it is possible that 2 of the foetuses were 
protected by antibody.
Pedersen et al. (1984) suggested that the foetus of cat P may 
have been infected by the transfer of latently infected maternal
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leucocytes across the placenta. This may be possible since 
Gruffydd-Jones (1982) demonstrated that congenital infection 
occurred after implantation and not in the ovum. Against this 
interpretation however is the fact that Rojko et al. (1982) failed 
to reactivate virus in circulating leucocytes in latently infected 
cats.
Since the first blood samples were not taken from the kittens 
of cat P until 2 weeks of age, it is possible that infection 
occurred post-natally and not congenitally as claimed. The source 
of infection may have been the milk, although if this were the case 
one might expect all 3 kittens to become viraemic within a few days 
of each other when maternally derived antibody had waned, as found 
in the present study. Although transmission of infection did occur 
from cat P to her kittens, it is unclear if infection was 
congenital or post-natal and the source of infection remains 
unresolved.
As discussed in Chapter 4, all latently infected cats have 
VNAs and most are thus resistant to reinfection with FeLV. However 
one cat in the present study, cat 4, spontaneously reactivated her 
latent infection to become persistently viraemic 1 1 weeks after her 
fourth litter was born. Reactivation of latency in vivo has 
previously only been reported when cats were treated with high and 
prolonged doses of corticosteroids (Post and Warren, 1980; Rojko _et 
al. , 1982; Pedersen et al., 1984). Cat 4 received no such therapy. 
She had been intermittently antigenaemic for approximately 2.5 
years, had always had low levels of VNAs and was producing 
infectious virus in her mammary glands. She may therefore have 
always been on the verge of becoming viraemic, and she eventually 
did so only after being exposed to 4 of her own litters of viraemic 
kittens and after being subjected to several stressful manipulat­
ions during her final pregnancy and lactation. It is possible, of 
course, that she always had a very low-grade viraemia which could 
not be detected by the methods of virus isolation used in this 
study. When viraemia became established her VNAs dropped below the 
levels of detection.
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Cats which thus spontaneously reactivate latent infections to 
become viraemic are a potential source of infection for susceptible 
cats.
Pedersen et al. (1984) placed 400 cats which had "recovered" 
from experimental FeLV infection in homes throughout the United 
States. Two of these cats became persistently viraemic within 6 
months of housing. One of the cats was exposed to a FeLV-positive 
companion but the other was not known to have been re-exposed to 
the virus. There is no conclusive evidence that these cats had 
really "recovered" before housing since VNA titres were not 
reported. However, if these cats did have VNAs it is possible that 
titres were low and that like cat 4 they reactivated latent FeLV 
infections upon challenge with viraemic cats, although this is 
impossible to determine with certainty.
In summary, most latent FeLV infections appear to be 
clinically and epidemiologically insignificant. However, a 
minority of cats like cat 4 which are antigenaemic, have low levels 
of VNAs and are latently infected, may be producing infectious 
virus at extramedullary sites such as the mammary glands. These 
cats are therefore a potential source of infection not only for 
their own kittens but for other susceptible cats in the household. 
Some of these cats may also spontaneously reactivate their latent 
infection to become viraemic. Such cats would complicate the 
control of FeLV in closed multicat households such as breeding 
colonies, and could be reponsible for the reappearance of viraemic 
cats in these households months or even years after the virus was 
believed to have been eradicated (Rojko et al., 1982; 0. Jarrett, 
personal communication).
92
CHAPTER 6
MECHANISMS OF THE CONTROL OF LATENCY
INTRODUCTION
In the previous three Chapters the duration and significance 
of latent FeLV infections were investigated. The present Chapter 
describes experiments which were carried out in cell culture in an 
attempt to understand how latent infections are established and 
maintained in cats.
Exposure of cats to FeLV may result in a persistent infection 
or in apparent recovery. When cats are experimentally inoculated 
with the virus the outcome is determined within 28 days of 
infection (Russell and Jarrett, 1978b; Rojko et al. , 1979a) and 
within about 70 days when naturally exposed to viraemic cats 
excreting the virus (Russell and Jarrett, 1978b). One of the 
factors which is related to the outcome of infection is whether or 
not the animal develops a neutralising antibody response. Cats 
which "recover" from infection produce VNAs and are resistant to 
reinfection, whereas cats which are persistently viraemic do not 
have serum VNAs.
However, as was found in the present study many of these 
"recovered" cats which have VNAs actually have a latent infection 
in their bone marrow. Although most latent infections last for a 
short period, as described in Chapter 4 approximately 10% of these 
infections are longterm.
It was believed that VNAs might have a role in the control and 
maintenance of latency for the following reasons. First, some 
latent infections can be reactivated in vivo by treating cats with 
prolonged and high doses of corticocosteroids (Post and Warren, 
1980; Rojko et al., 1982; Pedersen et al., 1984) although it is not 
known if reactivation is due to immunosuppression or to a direct 
effect of the corticosteroids on viral transcription (Rojko et al., 
1982) or effects on the bone marrow cells themselves.
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Secondly, as found in the present study and by Madewell and
Jarrett (1983) all latently infected cats have VNAs. Also, it is
known from the present study that spontaneous reactivation of the 
latent infection in cat 4, which resulted in persistent viraemia, 
coincided with the disappearance of VNAs from her serum.
Thirdly, as found in the present study and by others (Rojko et 
al., 1982; Madewell and Jarrett, 1983; Pedersen et al., 1984)
reactivation of virus occurs upon culture of latently infected 
marrow in the absence of VNAs.
The possible role of VNAs in the control and maintenance of 
latent FeLV infections was investigated in 3 ways. First, 
experiments were carried out to simulate in culture the conditions 
which might occur in the cat. Bone marrow cells from latently 
infected cats were cultured in the presence of cat sera from cats 
with latent infections, cats which had recovered from FeLV 
exposure, viraemic cats or unexposed cats. Reactivation of virus 
was found to be inhibited by sera containing VNAs. Secondly, the 
epitope which was involved in inhibition of viral reactivation was 
defined in similar experiments using mouse MCAs to FeLV proteins. 
Thirdly, attempts were made to understand the mechanisms by which
antibody appeared to control reactivation.
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MATERIALS AND METHODS
Reactivation inhibition (RI)
Inhibition of the reactivation of latent virus was attempted
by culturing bone marrow cells from 4 latently infected cats in
Flaskettes in the presence of various cat sera and mouse MCAs to
FeLV proteins. The cats used were cats 8 , 30, 31 and 32 (see Table 
2.1).
All cat sera and MCAs were heated to 56°C for 30 minutes
before use to inactivate complement.
a) Cat sera
Bone marrow cells, prepared as in Chapter 3, were suspended at
a concentration of 3.3 x lO^/ml in AFC10. A volume of 0.2 ml of
this suspension was added to each well of the Flaskette. An equal 
volume of cat serum which had already been diluted 1:2 in AFC10 was 
added to make a final concentration of 1:4 of cat serum in 
culture. The cells were incubated and were fed at 3-day intervals 
by replacing 0 . 2 ml of the culture fluid with a fresh 0 . 2 ml volume 
of the appropriate cat serum. The cells were grown in the 
continuous presence of the antibody for 10 days after which time IF 
was carried out to test for the presence of viral antigen. Bone 
marrow cells which were grown in the absence of antibody were 
included as a control.
The cat sera used were from cats 8 , 30, 31, 32, 41 , 42, 43,
44, 45 and 47 which were latently infected and cats 13, 14, 15, 16,
17 and 18 which had recovered from infection (see Table 2.1). 
Control sera were from 2 uninfected cats (cats 50 and 51) and 2 
viraemic cats (cats 52 and 53). Cats 52 and 53 were unvaccinated 
control cats in the experimental FeLV vaccine experiment detailed 
in Chapter 3. These cats were challenged oronasally at 14 weeks of 
age with 1 x 10^ fiu of FeLV-A/Glasgow-1 in 1 ml Leibovitz L-15 
medium.
b) Mouse MCAs
Bone marrow was grown as above but in the presence of mouse 
MCAs to FeLV proteins. These included 4 MCAs which neutralised 
FeLV-A (4611 E2, 19 B4, 3-17, 6-15) (Vedbrat et al. , 1983; Weijer 
et al., 1986), 6 which neutralised FeLV-BC (A415, C5E5, C8B11, 
C9E10, C13B5, C16C2) (Grant et al., 1983), 6 non-neutralising MCAs 
to FeLV-A which were directed against gp70 (C1G10, C10B7, G13D8, 
G14F5, 1 III Bl, 1 III C6 ) (Grant et al. , 1983) and 2 MCAs to p27 
(24IA3, 24IB3) (Lutz et al., 1983). Monoclonal antibodies A415, 
C5E5, C8B11, C9E10, C13B5, C16C2, C1G10, C10B7, G13D8, G14F5, 1 III 
Bl and 1 III C6 had been purified on protein A-sepharose columns by 
Dr. C.K. Grant and reconstituted in PBS at a concentration of 1 
mg/ml. The remaining MCAs were unpurified ascitic fluid with an 
unknown concentration of antibody.
Those MCAs which neutralised FeLV-A were diluted 1:50 in AFC10 
to make a final concentration of 1:100 in culture, and those MCAs 
which did not neutralise FeLV-A were used at a dilution of 1:10 in 
AFC10 to make a final concentration of 1:20 in culture. Cultures 
were maintained as above and IF was again carried out after 10 
days. Bone marrow cells which were grown in the absence of 
antibody were included as a control.
Titration of antibodies against latently infected bone marrow
Eight doubling dilutions of 12 cat sera and 4 MCAs which were 
effective in RI were made in AFC10. The dilutions chosen for each 
antibody spanned its VNA titre to FeLV-A. The 12 cat sera included 
4 from latently infected experimental cats (cats 41, 42, 43 and 
45), 4 from cats which had recovered from experimental infection 
(cats 16, 20, 54 and 55) and 4 from cats which had recovered from 
natural exposure in the field (cats 56-59).
The experimental cats had been infected in a variety of ways 
as shown in Table 2.1. Cat 20 had eliminated its latent infection 
at the time of the present experiment. Cats 54 and 55 recovered
96
from infection after receiving an oronasal dose of 1 x 10^ fiu of 
FeLV-A/Glasgow-1 in 1 ml Leibovitz L-15 medium at 16 weeks of age. 
Serum from an uninfected cat (cat 51) was included as a control.
The MCAs used were 4611 E2, 3-17A, 3-17B and 19 B4.
Antibodies 3-17A and 3-17B were different batches of the same MCA.
Bone marrow cells from 2 latently infected cats (cats 41 and 
42) were grown as above in the presence of 0.2 ml of the antibody 
dilutions. These cats had both developed latent infections 
following an oronasal dose of 1 x 10^ fiu of FeLV-A/Glasgow-1 in 1 
ml Leibovitz L-15 medium. Again, cultures were maintained as 
before, with IF being carried out after 10 days. The reciprocal of 
the highest dilution at which an antibody was still effective in 
completely inhibiting reactivation was called the RI titre.
Role of antibody in RI
It was important to determine whether or not those antibodies 
which were effective in RI exerted their effect by preventing the
production of virus, by killing cells which began to produce virus
or by preventing the spread of reactivated virus throughout the 
culture so that it could not be detected by IF.
Three experiments were carried out in an attempt to 
distinguish between these alternatives. In the first, a volume of 
0.2 ml of bone marrow cells from a latently infected cat (cat 45) 
at a concentration of 3.3 x 10^/ml in AFC20 was grown in the 
presence of neutralising antibody as described above. The antibody 
used was serum from either a recovered cat (cat 12) or cat 45 
itself, both of which had VNA titres of 128. The cultures were 
maintained as before with volumes of 0.2 ml of the antibodies being 
added for the first time to the bone marrow at day 0, 3 or 6 after 
initiation of the culture. The antibodies were used at a dilution 
of 1:15 to make a final concentration of 1:30 in culture. After 
antibody had been added to the cells, they were then grown in the
continuous presence of this antibody for the remainder of the
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experiment. Where no antibody was used the bone marrow cells were 
grown in a volume of 0.4 ml of AFC20. Fixed cell IF was carried 
out after 10 days.
The second experiment was similar to the first, involving the 
same bone marrow and sera. In this experiment, however, cultures 
were established in the presence of antibodies which were then 
removed 0, 3 or 6 days after the initiation of the culture. When 
antibody was removed after 3 or 6 days all of the original culture 
fluid was replaced with a volume of 0.4 ml of AFC20 in order to 
eliminate antibody. The cells were then grown in the absence of 
antibody for the remainder of the experiment and again IF was 
carried out on day 10.
In both of these experiments bone marrow cells from a viraemic 
cat (cat 62) and an uninfected cat (cat 61) were treated in a 
similar manner to the cells of cat 45 and were included as 
controls. Cat 62 became infected after receiving an oronasal dose 
of 1 x 106 fiu of FeLV-A/Glasgow-1 in 1 ml of Leibovitz L-15 medium 
at 14 weeks of age.
In the third experiment bone marrow from a viraemic cat (cat 
63) which became infected after receiving a subcutaneous dose of 
1.3 x 10^ fiu of FeLV-A/Glasgow-1 in 1 ml of Leibovitz L-15 medium 
at 8 weeks of age and an uninfected cat (cat 64) were co-cultivated 
for 10 days in varying proportions in the continuous presence of 
serum from either cat 12 or cat 45 as described above. The ratio 
of bone marrow cells of cat 63 to those of cat 64 were 1:10; 1:50; 
1:100; 1:500; 1:1000 and 1:5000. Wells containing only cells of 
cat 63 or 64 were also included. The cultures were maintained as 
before with IF being carried out after 10 days. Similar cultures 
grown in the absence of antibody were included as controls. Each 
of these three experiments was done in duplicate.
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RESULTS
Reactivation inhibition
a) Cat sera
As shown in Table 6.1, all of the cat sera which contained 
VNAs to FeLV-A, i.e. the sera from latently infected or recovered 
cats, were effective in inhibiting reactivation of latent virus as 
determined by the absence of viral antigen upon IF of the bone 
marrow cultures. The sera from the uninfected and viraemic cats 
which contained no VNAs did not inhibit virus reactivation. The 
results were independent of the source of the bone marrow cells. 
Fig. 6.1 shows IF carried out on bone marrow which had been 
cultured for 10 days in the presence of cat sera which either did 
not contain (Fig. 6.1a) or did contain (Fig. 6.1b) VNAs to FeLV-A.
b) Mouse MCA
Those MCAs which neutralised FeLV-A were effective in 
inhibiting reactivation of latent virus, whereas those which 
neutralised FeLV-BC were not. Likewise, the non-neutralising MCAs 
directed against FeLV-A gp70 or those against the core protein, 
p27, were unable to inhibit virus reactivation, even when used at 
high concentrations. A list of the MCAs used and their efficacy in 
RI is given in Table 6.2.
Titration of antibodies against latently infected bone marrow
The RI titres of the cat sera and MCAs which were used in a 
series of dilutions on the bone marrow cells of 2 latently infected 
cats are listed in Table 6.3. Also shown are the titres of these 
antibodies as determined by virus neutralisation.
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TABLE 6.1
Reactivation inhibition of FeLV latency with cat sera
Cat serum Cat numbers VNA RI
Autologous latent 8 , 30, 31 or 32 + +
Heterologous latent 41, 42, 43, 44, 45, 47 + +
Heterologous recovered 13, 14, 15, 16, 17, 18 + +
Viraemic 52, 53 - -
Uninfected 50, 51 — —
VNA = virus neutralising antibodies to FeLV-A
RI = reactivation inhibition activity
+ = present
- = absent
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FIG. 6.1 Fixed cell IF carried out on latently infected bone 
marrow after being cultured for 10 days in the 
continuous presence of cat serum.
a. The cat serum used contained VNAs to FeLV-A. No 
viral p27 antigen can be detected.
b. The cat serum used did not contain VNAs to FeLV-A. 
Virtually all of the cells contain p27 antigen.
The preparations were counterstained with 0.2% carbol 
chromotrope in water in order to remove non-specific 
fluorescent granules in myeloid cells which are arrowed.
Magnification x 250
• 1
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TABLE 6.2
Reactivation inhibition of FeLV latency with MCAs
MCA______________________Specificity__________________ VNA________ RI
4611 E2 gp70 FeLV-A neutralising + +
19 B4 " + +
3-17 " + +
6-15 .. + +
A4 15 gp70 FeLV-A non-neutralising
C5 E5
C8 Bll
C9 E10
C13 B5
C16 C2
Cl G10 gp70 FeLV-BC neutralising
CIO B7
G13 D8
G14 F5
1III Bl
1III C6
241 A2 p27 non-neutralising
241 B3
None
VNA = virus neutralising antibodies to FeLV-A
RI = reactivation inhibition activity
+ = present
- = absent
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TABLE 6.3
Virus neutralising and reactivation inhibition titres of antibodies
Antibody VNA titre
RI 
Cat 41
titre
Cat 42
Monoclonal
4611 E2 12800 8000 16000
3-17A 1024 2048
3-17B 2048 2048
19 B4 512 4096
Latent cat
41 128 64 256
42 128 256 512
43 64 64 512
45 512 512 128
Recovered experimental cat
16 1024 2048 2048
20 256 512 256
54 128 512 32
55 128 64 64
Recovered field cat
56 128 128 64
57 512 256 4096
58 32 128
59 64 512 2048
Uninfected cat
51 0 0 0
VNA = virus neutralising antibody to FeLV-A 
RI = reactivation inhibition
Where no result is given the test was not done.
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Correlation of RI and VNA titres
The RI and VNA titres of the antibodies used were plotted as 
shown in Fig. 6.2. They were found to have a correlation co­
efficient of 0.89.
Role of antibody in RI
In the first 2 experiments identical results were obtained 
when using the serum of either cat 12 or cat 45.
When antibody was added to the latently infected marrow on day 
0 or day 3, antigen could not be detected when IF was carried out 
on day 10. However, when addition of antibody was delayed until 
day 6, small foci of cells containing antigen could be detected on 
day 10.
When the latently infected marrow was grown in the absence of 
antibody for 10 days, as expected virus reactivation occurred and 
antigen could be detected in almost all of the cells. When the 
cells were grown in the presence of antibody for 3 days followed by 
its absence for 7 days small foci of infected cells were observed. 
However, when the cells were grown in the presence of antibody for 
6 days followed by its absence for only 4 days, antigen was not 
detected.
Similar experiments carried out on bone marrow cells from the 
uninfected cat failed to detect antigen. When bone marrow from the 
viraemic cat was used virtually all of the cells in every instance 
contained antigen, even when antibody was continuously present for 
10 days.
The presence of antibody did not appear to have a non-specific 
cytotoxic effect since there was no difference in the appearance of 
the cells which had been grown in its continuous presence or 
absence for 10 days.
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FIG. 6.2 Correlation between titres of antibody in virus 
neutralisation and reactivation inhibition.
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The third experiment was designed to determine whether or not 
serum from latently infected cats containing VNAs could prevent the 
spread of FeLV through bone marrow cultures. This experiment, 
involving the co-cultivation of bone marrow cells from a viraemic 
and an uninfected cat, proved difficult to quantitate when IF was 
carried out after 10 days in culture, but unequivocal qualitative 
results were obtained which are summarised in Table 6.4.
In the control cultures which were grown in the absence of 
antibody, those wells which contained only cells from the viraemic 
cat contained large quantities of free antigen and antigen could be 
demonstrated in the cytoplasm of virtually every cell. "Free" 
antigen was seen as light punctate fluorescence over the glass 
surface of the culture well and was presumed to represent the p27 
which is shed from FeLV infected cells in large quantities, 
probably in the form of a glycosylated gp40 precursor (Neil et al., 
1980b). Similar results were obtained when the ratio of cells from 
the viraemic cat to those from the uninfected cat was decreased 
until this ratio was 1:500. At this ratio fewer antigen-containing 
cells were detected and no free antigen was evident. At ratios of 
1:1000 and 1:5000, or where all of the cells were from the 
uninfected cat, no cells with antigen could be detected.
When the cells were co-cultivated in the presence of antibody 
for 10 days the same results were obtained when using the serum of 
either cat 12 or cat 45. Where the culture contained only cells 
from the viraemic cat essentially all contained antigen and free 
antigen was present in the culture. However, where the ratio of 
cells from the viraemic to the uninfected cat was 1:10 only focal 
areas of cells containing antigen were seen. It was possible to 
detect individual cells containing antigen adjacent to cells which 
did not contain antigen. Where the ratio was 1:50 very few cells 
contained antigen, and only occasional individual 
antigen-containing cells were detected at 1:100. Where there were 
fewer than 1:100 cells from the viraemic cat, no antigen was 
detected.
106
TABLE 6.4
Co-cultivation of bone marrow cells from a viraemic and an
uninfected cat in the presence or absence of neutralising antibody
Ratio of cells No antibody 
vi raemi c :uninfe ct ed
Neutralising 
antibody from 
cat 12 or cat 45
All viraemic Antigen in all cells 
Free antigen
Antigen in all cells 
Free antigen
1 : 10 •• Antigen in foci of cells 
No free antigen
1 : 50 " Very few cells with 
antigen
1 : 100 it Occasional cells with 
antigen
1 : 500 Fewer cells with antigen
No free antigen No antigen
1 : 1000 No antigen ••
1 : 5000 •• it
All uninfected »i ••
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Although it was not feasible to count the antigen-containing 
cells it was clear that as the number of cells from the viraemic 
cat which was originally cultured decreased, then the number of 
cells which contained antigen after 10 days in culture in the 
continuous presence of antibody also decreased.
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DISCUSSION
Initial experiments described in this Chapter showed that the 
reactivation of latent FeLV from cultured bone marrow could be 
inhibited by culturing the bone marrow cells in the continuous 
presence of sera from latently infected or recovered cats, and that 
sera from persistently viraemic or uninfected cats were not
effective. The fact that sera from latently infected and recovered 
cats contain VNAs and those from viraemic and uninfected cats do 
not strengthen the belief that these antibodies may have a role in 
the maintenance of latent infections.
In order to identify the determinant with which these 
antibodies reacted, mouse MCAs to FeLV proteins were used in the 
same manner as the cat sera. Those MCAs which reacted with a
non-neutralising epitope of FeLV-A gp70 or the neutralising epitope
of FeLV-BC gp70 or the core protein, p27, were not effective in 
RI. It is significant that the cats used in this study were
infected with FeLV-A since those MCAs which reacted with the 
neutralising epitope of FeLV-A gp70 inhibited the reactivation of 
virus from cultured latently infected bone marrow cells. This 
would suggest that the epitope involved in RI is the same as that 
which is involved in virus neutralisation and that VNAs may be at 
least in partial control of latency in vivo. The RI and VNA titres 
of the antibodies which were effective in RI were correlated and 
gave a correlation co-efficient of 0.89. This result suggested 
that the two assays measured the same activity and reinforced the 
belief that VNAs played a role in the control of latency.
Attempts were then made to determine the role of neutralising 
antibody in RI. The possibilities considered were that the 
antibody prevented viral expression in latently infected cells, 
killed cells which began to produce virus, and/or prevented the 
spread of reactivated virus throughout the culture by virus 
neutralisation.
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In order to study the possibility that antibody killed cells 
from which virus had been reactivated a set of experiments was 
initiated where antibody was either added or removed from latently 
infected bone marrow cells at various times after the onset of 
culture. IF was carried out on day 10 in order to detect 
reactivated virus in the form of cytoplasmic antigen. When 
latently infected bone marrow cells were cultured in the absence of 
antibody for 3 days followed by its presence for 7 days there was 
no detectable antigen in the cells. This finding could be 
interpreted in a number of ways. Either reactivation did not occur 
within 3 days or if it did, then the presence of antibody for a 
further 7 days caused a reversal of this phenomenon. A third 
possibility is that reactivation did occur, but that the antibody 
then prevented spread of virus throughout the culture, and 
therefore prevented its detection by IF, because as shown by 
infectious centre assays in Chapter 3, the proportion of cells with 
latent infections is very small and individual antigen-containing 
cells may not be detected by IF.
When latently infected bone marrow was grown for 6 days in the 
absence of antibody and then in its presence for 4 days foci of
cells containing antigen could be detected. Therefore it was 
obvious that reactivation of virus had occurred within 6 days and 
was not reversed by the addition of antibody for the subsequent 4 
days. It is possible that reversion might have occurred if
antibody had been present for longer than 4 days. However, from 
the results obtained with the bone marrow cells from the viraemic 
cat it would appear that once an infection had become established
and cells were producing virus it could not be suppressed with the
concentrations of antibody used here, since even after the 
continuous presence of antibody for 10 days, antigen was still 
detected in these virus-producing cells. Although quantitation of 
antigen production was not attempted the intensity of fluorescence 
obtained appeared similar when bone marrow cells from the viraemic 
cat were grown in the continuous presence or absence of antibody 
for 10 days. Therefore, the detection of foci of infected bone 
marrow cells from the latently infected cat after being cultured 
for 6 days without antibody followed by 4 days with antibody, may
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be a reflection of the fact that this antibody could not suppress 
viral expression in cells which had an established infection. 
Alternatively it could merely indicate that the spread of virus 
throughout the culture was prevented by the neutralisation of 
reactivated virus.
Other experiments showed that when latently infected bone 
marrow cells were grown in the presence of antibody for 3 days and 
then in its absence for 7 days, foci of infected cells could be 
seen indicating that within 3 days the antibody had not killed the 
latently infected cells and that they were still capable of 
producing virus when the antibody was removed. However, the 
antibody did have an effect on viral production within these 3 days 
because only small foci of infected cells were present in contrast 
to the situation in which cells were grown in the absence of 
antibody for 10 days when virtually all of the cells contained 
antigen.
When bone marrow cells were grown in the presence of antibody 
for 6 days and then in its absence for 4 days no infected cells 
were detected. This could be because these 4 days were not long 
enough to allow viral reactivation after 6 days of inhibition, or 
it may be due to antibody-mediated killing of cells which began to 
reactivate virus. However, this latter possibility appears to be 
unlikely since the presence of antibody in bone marrow cell 
cultures from the viraemic cat which were producing virus had no 
apparent cytolytic effect. It is possible, therefore, that 
reactivation may have occurred from the latently infected bone 
marrow cells if they had been grown in the absence of antibody for 
longer than 4 days since, as described above, antigen could not be 
detected when these cells were grown in the absence of antibody for 
3 days followed by its presence for 7 days, but could be detected 
when they were grown in the absence of antibody for 6 days followed 
by its presence for 4 days. These results would suggest that the 
crucial time for reactivation of latent virus under these 
conditions is between 3 and 6 days after the onset of culture.
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From the results obtained with bone marrow cells from the
uninfected cat it appeared that the antibody did not have a 
non-specific cytotoxic effect since cells grown in either the
continuous presence or absence of antibody for 10 days appeared
equally healthy. The lack of infected cells in these cultures
proved that the fluorescence obtained in the cultures from the 
latently infected and viraemic cats was specific.
It would appear therefore that neither a cytolytic nor a 
cytotoxic effect was involved in RI and that once an infection 
became established, as in cells from the viraemic cat, the antibody 
had no inhibitory effect on viral expression. However, it was 
still unclear if this antibody prevented the spread of virus or had 
a direct effect on viral production. In an attempt to answer this 
question an experiment was carried out involving the co-cultivation 
of varying proportions of bone marrow cells from a viraemic and an 
uninfected cat in the continuous presence of antibody for 10 days. 
From previous results it was known that the antibody was not 
non-specifically cytotoxic, that it was not cytolytic for virus- 
producing cells, and that it did not appear to suppress viral 
production in cells with established infection. Therefore, by 
mixing virus-producing with non-producing cells it was hoped to 
determine whether or not the antibody prevented the spread of virus 
throughout the culture. If this were the case, then where the 
ratio of producing cells to non-producing cells was 1 to 10 then it 
would be expected that 10% of the cells would contain antigen after 
10 days in culture, whereas if the antibody were not having this 
effect it would be expected that the infection would have spread to 
the non-producing cells, thus resulting in more than 10% of the 
cells containing antigen.
However, in practice the experiment proved difficult to 
quantitate. From the results obtained when the cell mixtures were 
grown in the absence of antibody it was evident that IF was not as 
sensitive an assay for detecting infected cells as was the 
infectious centre assay described in Chapter 3. In the experiments 
described here it is clear that the limit of detection by IF of
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cells which contain antigen lies between 1:500 and 1:1000 whereas 
the infectious centre assay detected as few as 3 infected cells per 
million.
Nevertheless when the mixtures of bone marrow cells from the 
viraemic and the uninfected cats were grown in the presence of 
antibody it appeared that this antibody inhibited the spread of 
infection from the cells of the viraemic to those of the uninfected 
cat since as the number of the former which were originally
cultured decreased, then so did the number of cells which contained 
antigen after 10 days in culture.
By contrast, when the cells were grown in the absence of 
antibody the infection spread to the cells from the uninfected cat, 
and it was not until the proportion of cells from the viraemic to 
those from the uninfected cat was 1:500, that it was obvious that 
the infection had not spread throughout the culture within 10 days.
The fact that individual cells containing antigen could be
seen adjacent to cells which did not when grown in the presence of 
antibody also indicated that the antibody prevented the spread of 
infection.
These results may suggest therefore that a "latent" FeLV
infection in vivo might not be a true latent infection but might 
represent a low-grade active infection present in a small
proportion of bone marrow cells, with VNAs preventing virus from 
spreading to other cells in the bone marrow and from entering the
blood. This may explain why some cats, like cat 4 described
previously, appear to be "latently" infected but have viral antigen 
in their blood and are producing infectious virus at extramedullary 
sites, and may confirm the suggestion that these cats are on the 
verge of becoming viraemic, as was proven in the case of cat 4.
It is probable that other immumnological mechanisms as well as 
VNAs are also involved in the control of latency. Rojko et al.
(1982) found that cytotoxic T-cells reacted with autologous
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latently infected bone marrow cells after virus had been react­
ivated upon their culture, but not on freshly aspirated bone marrow 
cells which were not expressing FeLV antigens. Therefore a cell 
mediated immune response may also participate in the control of 
latency by removing cells which express virus.
Another possibility is that an intact complement system may be 
important in the maintenance of latent infections. Kraut et al. 
(1985) treated 5 latently infected cats with cobra venom factor 
which causes a depletion of complement. Before treatment none of 
the cats was positive for antigen in circulating blood leucocytes 
or in freshly aspirated marrow. However one week after treatment, 
3 of these cats became positive for antigen in circulating 
leucocytes and in fresh bone marrow cells, thus indicating an 
increase in viral antigen production. At this time these cats had 
decreased levels of complement.
From these results it is probable that the control of latent 
FeLV infections in vivo is complex, involving a combination of 
neutralising antibody production, cell mediated immunity and 
complement.
Although the results obtained in the present study show that 
neutralising antibody prevents the spread of virus from latently 
infected cells in vitro it is still unknown whether or not it has a 
direct effect on individual cells by inhibiting the release of 
virus. Ways in which these alternatives might be distinguished and 
the possible significance of the results of the present study for 
other persistent viral infections are discussed in Chapter 7.
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CHAPTER 7
GENERAL DISCUSSION
The aims of the studies described here were to determine the 
prevalence and duration of latent infection in cats exposed to
FeLV, to assess the clinical and epidemiological consequences of 
latency and to define the mechanisms by which the latent state is
maintained. In this Chapter the extent to which these aims were
achieved is discussed and where appropriate further studies to 
investigate questions raised in the present work are suggested.
Particular attention is paid to the mechanisms by which latency may 
be controlled in vivo.
Cats with latent FeLV infections were identified by the 
culture of freshly aspirated bone marrow cells which resulted in 
reactivation of the latent virus. Infectious virus could then be 
detected in cell culture fluids by virus isolation, usually within 
2 weeks of the initiation of the culture. An immunofluorescence 
technique was developed which could detect viral antigen in the 
cytoplasm of bone marrow cells after only 1 week of culture. Thus, 
culturing of bone marrow cells proved to be a rapid and effective 
method of identification of latently infected cats.
Another method of identifying such cats involves treating them 
with corticosteroids resulting in virus reactivation, and viraemia 
(Post and Warren, 1980; Rojko et al. , 1982; Pedersen et al.,
1984). However, this method is relatively insensitive since only a 
proportion of the cats develops viraemia, and only after prolonged 
administration of high doses of the drugs. Corticosteroid therapy 
is also an inhumane method of detecting latency because the 
resulting viraemia is obviously undesirable since, if persistent, 
would predispose to the FeLV-related diseases detailed in Chapter 
1. It is for this reason, however, that it would be important to 
determine the effects on latent infections of the routine use of 
corticosteroids in veterinary practice in the therapy of 
inflammatory conditions or autoimmune disease.
It would also be of interest to investigate the effect of 
megestrol acetate (Ovarid; Glaxovet) which is widely used not only 
as a contraceptive but also in the therapy of diseases such as 
flea-bite hypersensitivity and eosinophilic granulomata. The
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mechanism by which this drug affects the latter conditions is not 
known, but it is believed to have a corticosteroid-like activity 
since it will produce adrenocortical suppression and atrophy in 
normal cats (Chastain et al., 1981). The possible influence of 
therapeutic doses of both corticosteroids and megestrol acetate on 
latent infections should be the subject of a future study.
From the studies of the experimental multicat household 
detailed in Chapter 4 it was found that in such FeLV-infected 
households the proportion of the non-viraemic cats which harbour 
latent infections may be high at any one time. It was also shown 
by the use of infectious centre assays that the proportion of 
latently infected cells in the marrow is variable between cats, but 
low. A remaining question is which cells in the marrow contain the 
latent virus. Rojko et al. (1982) suggested that latent virus was 
present in immature but not in differentiated myeloid cells 
although this has not been demonstrated unequivocally. The fact
that there are so few cells which harbour the latent infection 
makes their identification difficult. However, it may be possible 
to enrich for the latently infected cells by fractionating the bone 
marrow cells on a cell sorter (FACS II; Becton Dickinson). The 
individual fractions could then be cultured and the presence of 
reactivated virus detected as previously described for whole bone 
marrow. Identification of the cells which produce virus would then 
depend on morphology by histological staining or on colony assay 
(Onions et al., 1982) since there are as yet no markers for the 
different types of feline myeloid cells. From the results of the 
infectious centre assays carried out in the present study it 
appears that virus reactivation occurs quickly because the size of 
the transformed foci produced by bone marrow cells from latently 
infected cats was similar to those produced by marrow cells from 
viraemic cats or by chronically infected fibroblasts (FEA/FeLV-A) 
both of which continuously produce virus. Therefore, it would not 
be unreasonable to attempt identification of latently infected
cells on morphological grounds since they are unlikely to alter in
the time necessary for viral reactivation to occur.
1 1 6
Alternatively, cells in which virus is reactivated could be 
sorted by IF. The bone marrow could be cultured in order to allow 
virus reactivation to occur. The cells could then be resuspended 
and the surface of virus-expressing cells labelled with a mouse MCA 
to FeLV gp70. Labelled cells could then be separated on a cell 
sorter. Identification of the cells would again be by morphology 
or colony assay.
What is clear from the present study is that the majority of 
latent infections are short-lived, being eliminated within 2.5 
years of exposure to the virus. What is unclear is the mechanism 
by which latency is terminated. From the findings of Rojko et al.
(1982) it is possible that latent virus is present in myeloid 
precursor cells and that latent infection ends when these cells 
have differentiated, have completed their natural life span and 
have been removed from circulation. The duration of a latent 
infection would then be dependent on the type and the number of 
cells which were infected initially. It might be expected that 
latency would last longer if a large number of immature cells were 
infected than if infection involved only a few cells which were 
reaching the final stages of maturation. It is possible that the 
small proportion of longer-lived latent infections (like cat 8) is 
a reflection of the virus being present in very primitive stem 
cells which are not eliminated, or even in lymphocytes which are 
themselves long-lived.
An alternative explanation is that latency ends as a result of 
an immunological response. Neutralising antibody which is present 
in all latently infected cats may kill any virus which is produced 
and/or kill any cell which begins to express virus. On the other 
hand cell mediated immunity may be responsible for killing 
virus-producing cells. If either of these events does occur then 
it is likely that latency ends when all of the infected cells have 
been killed.
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However, the possibility that latency does not end must not be 
forgotten. The methods of virus isolation from bone marrow culture 
fluids, fixed cell IF on cultured bone marrow cells and infectious 
centre assays used in this study may not be sufficiently sensitive 
to detect infected cells. This problem will be discussed in more 
detail later.
The next objective of this study was to determine the
mechanisms which were responsible for initiating and controlling 
latent infections. For the reasons discussed in Chapter 6 it was 
thought that VNAs probably had a role in the maintenance of latency 
in vivo.
From the experiments involving the culture of latently
infected bone marrow cells in the continuous presence of cat serum 
it was found that those sera which contained VNAs from either 
latently infected or recovered cats inhibited the reactivation of 
latent virus. By the use of mouse MCAs to FeLV proteins it was 
determined that the epitope with which this antibody reacted was 
that on the gp70 which is also involved in virus neutralisation. 
It was therefore concluded that, at least in vitro, antibody which 
neutralised the infecting virus had a role in the maintenance of
latency. This was further confirmed when it was found that the
virus neutralising and reactivation inhibition titres of these 
antibodies were closely correlated suggesting that the two assays 
were measuring the same activity and that VNAs were important in 
the control of latent infections in vivo.
When neutralising antibody was either added to or removed from 
latently infected bone marrow cells at varying times after the 
onset of culture, it was found that the inhibitory effect of the 
antibody on virus reactivation was reversible but that once 
reactivation had occurred and the cells were expressing p27, the 
addition of antibody had no such effect. Similarly, antibody could 
not stop virus production from bone marrow cells from viraemic cats 
or from chronically infected FEA/FeLV-A cells.
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In summary, neutralsing antibody inhibited reactivation of 
FeLV from latently infected bone marrow cells in vitro. This 
effect was reversible, but if virus were allowed to reactivate 
prior to antibody addition, then inhibition did not occur.
The mechanism by which neutralising antibody inhibits virus 
reactivation is not yet known. It is possible that the antibody 
has an effect on individual latently infected cells by binding to 
gp70 expressed on the cell surface and inhibiting virus 
production. The action of the antibody binding to this antigen may 
initiate a transmembrane signal which prevents further expression 
of viral proteins. The operation of this mechanism would obviously 
require the continuous transcription and translation of the env 
gene in order that gp70 would be expressed on the cell surface. 
However, it is not known if such transcription occurs. It would be 
necessary to use the technique of in situ hybridisation which 
detects viral RNA in individual cells to determine whether or not 
transcription of any of the FeLV proteins occurred (Harper et al., 
1986).
From the results of the present study neither p27 nor gp70 
were detected by fixed or live cell IF in uncultured freshly 
aspirated bone marrow cells from latently infected cats. However, 
as described in Chapter 6 IF proved not to be a very sensitive 
method of detecting antigen-producing cells, being capable of 
detecting only between 1:500 and 1:1000 cells which produced p27. 
Approximately 1 to 10% of these cells produce gp70 (0. Jarrett, 
personal communication). The results of infectious centre assays 
discussed in Chapter 3 showed that the numbers of latently infected 
cells ranged from 3 to 400 per million cells. Therefore, even if 
viral antigen production did occur, it would not be possible to 
detect it by the methods of IF described in this study. The 
detection of gp70 by IF may be further compromised by the presence 
of bound autologous antibody.
The method of in situ hybridisation has proven to be a much 
more sensitive method of detecting transcribed RNA in uncultured
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cells. For example, Harper et al. (1986) showed that this 
technique detected as few as 1 in 100,000 lymphocytes in peripheral 
blood or lymph nodes which contained the RNA of human immuno­
deficiency virus (HIV). This technique is currently being 
developed in order to detect transcription of FeLV genes in bone 
marrow cells from latently infected cats. It is possible that 
differential transcription of these genes occurs since env can be 
transcribed independently of gag and pol (Neil and Onions, 1985). 
It would therefore be possible for gp70 to be expressed in the 
absence of any of the gag proteins. Thus, gp70 may be expressed on 
the cell surface, and the action of neutralising antibody binding 
to it may then initiate a signal which prevents further 
transcription of viral genes.
Alternatively, the entire FeLV genome may be transcribed and 
the binding of antibody to the gp70 may inhibit assembly of the 
viral proteins and final maturation and budding of the virus, thus 
preventing the production of infectious virus particles.
It is known that other viruses can persist in a non-productive 
state and the mechanisms involved in the persistence of some of 
these have been studied. Probably the most fully investigated are 
the paramyxoviruses and in particular measles virus.
Following an acute infection, measles virus can persist in 
brain tissue of individuals in the presence of a fully competent 
immune system and in later life can cause subacute sclerosing
panencephalitis (SSPE) (Joseph and Oldstone, 1975). It was 
suggested that the virus persisted in SSPE patients because 
neutralsing antibody bound to viral antigens expressed on the cell 
surface caused a rearrangement of these antigens (Joseph and 
Oldstone, 1975; Lampert et al., 1975; Oldstone, 1977). This 
phenomenon is known as "antigenic modulation" and was first
described by Boyse et al. (1963).
In vitro studies showed that cells which were chronically
infected with measles virus could be lysed in the presence of
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optimal levels of anti-viral IgG and complement and that it was the 
alternative rather than the classical complement pathway which was 
initiated (Joseph et al. , 1975). However, when these cells were 
grown in the presence of antibody with moderately decreased levels 
of complement, they were not lysed (Joseph et al., 1975; Gorman and 
Lachmann, 1982). Instead, antigenic modulation occurred as 
demonstrated by the stripping of viral antigen from the cell 
surface. Therefore, if complement levels were depleted the cells 
escaped the immune system. Similar findings have also been
reported by Fujinami and Oldstone (1985).
The suggestion of Joseph and Oldstone (1975) and Oldstone 
(1977) that antigenic modulation occurred in vivo in SSPE patients 
is plausible because high levels of antibody but not complement
were present in the cerebrospinal fluid of these patients. This 
was later confirmed by Gorman et al. (1980) who found that patients 
with SSPE had greatly enhanced levels of antiviral antibody in the 
cerebrospinal fluid although this was noted to be part of a general 
systemic hyperimmune response to the virus. Infected cells thus
escape from immune destruction and the virus persists. The ways in
which measles virus persists and escapes immunosurveillance have 
been reviewed by Oldstone and Fujinami (1982).
The modulation which occurred in vitro peaked at 24 to 34 
hours after the addition of antibody. There was no re-expression 
of viral antigen when antibody was present and once modulation had 
occurred the addition of complement or cytotoxic T-cells had no 
effect (Gorman and Lachmann, 1982). However, this phenomenon was 
reversible, as demonstrated by the reappearance of viral antigen 
upon removal of the antibody (Fujinami and Oldstone, 1980; Gorman 
and Lachmann, 1982) although the rate at which this happened 
depended on how long the antibody had been present (Joseph and 
Oldstone, 1975).
The molecular mechanisms involved in the antigenic modulation 
of measles virus have been investigated. Fujinami and Oldstone 
(1980) found that there was a decrease in the expression of viral
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polypeptides on the surface of acutely infected cells upon the 
addition of antibody. These authors suggested that alterations in 
the polypeptides may lead to abberations in the alignment of viral 
proteins and synthesis of virus at the membrane (Fujinami and 
Oldstone, 1979; 1980).
Joseph and Oldstone (1975) reported that in acute measles 
infections cells are killed due to the expression of a viral 
protein, the fusion protein, on the cell surface which fuses 
infected cells which are subsequently lysed. In persistent measles 
infection, where antigenic modulation occurs, there is a decrease 
in the expression of the fusion protein, therefore the infected 
cells do not fuse and are not killed. Thus the infection persists 
(Fujinami and Oklsfcbne, 1980).
Interestingly the binding of antibody to viral antigens on the 
cell surface not only resulted in antigenic modulation but also 
interfered with the expression of viral antigens inside the cell. 
There was a decrease in the production of viral haemolysin and 
phosphoprotein upon the addition of antibody (Fujinami and 
Oldstone, 1979). It is not known if these proteins are even 
transcribed under these conditions. Such a mechanism would require 
a transmembrane signal but what this might be is also unknown.
In summary, measles virus persists in its host in the presence 
of high titres of neutralising antibody which binds to and causes 
modulation of viral antigens expressed on the cell surface. The 
binding of antibody also alters the expression of viral antigens 
inside the cell although it is not known how this is initiated. 
These processes are reversible upon the removal of antibody.
Another paramyxovirus, canine distemper virus (CDV) which is 
very closely related to measles virus can also persist in its 
host. Like measles virus, in acute infections the infected cells 
are lysed by the activation of the alternative complement pathway 
by the binding of antiviral antibody to viral antigens expressed on 
the cell surface (Gorman, 1983). As observed in persistent measles
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virus infections, in persistent CDV infections there are decreased 
levels of complement and the binding of antibody to cell surface 
viral antigen causes antigenic modulation (Gorman and Lachmann,
1982). The infected cells thus escape the host's immune system and 
the virus persists.
Other paramyxoviruses have been found to persist in human bone 
marrow cells. These include simian virus 5 (SV5) and human
parainfluenza viruses types 1 and 3 (Goswami et al. , 1984). Prior 
to culture SV5 antigen could be demonstrated in individual bone 
marrow cells by IF, but upon culture for 5-7 days the antigen 
spread to neighbouring cells to produce foci of infection. 
However, the infection did not become generalised and degeneration 
of the cells occurred as the antigen spread. The parainfluenza 
viruses did not spread. The presence of neutralising antibody to 
SV5 in the sera of patients correlated well with the detection of 
antigen in the bone marrow cells. Therefore it has been suggested 
that antigenic modulation may occur to prevent spread of virus in 
vivo and allow the virus to persist (Russell and Goswami, 1984). 
However, the prevention of the spread of antigen through cultured 
bone marrow cells by the addition of neutralising antibody has not 
been attempted.
Thus, paramyxovirus can persist in the host and it is thought 
that the mechanism of persistence involves the binding of 
neutralising antibody to cell surface viral antigens resulting in 
antigenic modulation.
The persistence of herpes simplex virus (HSV) has also been 
studied in detail. HSV may form a latent infection which in man 
can be reactivated by stimuli such as pyrexia, skin trauma and 
ultraviolet light (Wildy et al., 1982). It has long been thought 
that the latent virus resides in neurones and this was confirmed by 
McLennan and Darby (1980). Latent HSV can be detected by 
co-cultivating cells from infected ganglia with susceptible cells 
(Stevens and Cook, 1971; Openshaw et al., 1979) leading to
reactivation of the virus which can then be detected by the 
presence of a characteristic cytopathic effect. Detection of
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infected cells has been attempted in a number of other ways*
Immunofluorescence carried out on fresh ganglia of 50 latently 
infected mice failed to detect viral antigen (McLennan, 1981).
Therefore if there is expression of antigen it is below the levels 
of detection by this method. However, the use of infectious centre 
assays on disaggregated ganglia showed that only 0.1% of cells in 
the ganglia were infected (Walz et al. , 1976). Therefore, even if
antigen were expressed it would be unlikely to be detected in so
few cells by IF. McDougall and Galloway (1978) detected viral mRNA
by in situ hybridisation in many neurones although it is believed
/
that these cells may have been undergoing virus reactivation at 
that time.
Stevens and Cook (1974) suggested that neutralising antibody 
controlled latent HSV infections. However, this was not confirmed 
since when mice were infected with virus and were given rabbit 
hyper-immune anti-herpesvirus serum between 3 and 144 hours after 
infection they developed latent infections within 1 to 2 days which 
remained in over 90% of the mice even after the antibody had 
disappeared, approximately 2 months after administration (Sekizawa 
et al., 1980). Latent virus could be reactivated by trauma to the 
inoculation site and neutralising antibodies reappeared in the sera 
of the mice at this time. Since this antibody was not detected 
while the virus was latent Sekizawa et al. (1980) concluded that 
expression of viral antigen either did not occur during latency or 
it occurred at levels too low to initiate a detectable neutralising 
antibody response. Neutralising antibody therefore appeared to be 
unimportant in the control of latent HSV infections. However, it 
cannot be ruled out that non-neutralising antibody plays a role in 
the maintenance of these infections (Nash, 1981). It has also been 
suggested that cell mediated immunity may play a part here since 
this is important for the protection of the host against acute 
infection (Lodmell et al., 1973; Oakes, 1975) and patients
undergoing recrudescence had decreased cell mediated immune 
responses (Wilton et al. , 1972; Shillitoe et al., 1977).
On the other hand HSV latency may occur because the virus is 
present in non-permissive cells (Sekizawa et al. , 1980) or it may
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be that it is maintained by a low level of virus replication or 
intermittent spontaneous reactivation (Scriba, 1975; Hill and 
Blyth, 1976).
The molecular biology of HSV latency has recently been 
reviewed by Cantin et al. (1985). It has been found that almost 
the entire genome is present in the brain tissue of latently
infected people (Fraser et al., 1981) and mice (Rock and Fraser,
1983) although it is not known in what form the genome is present. 
It may exist as a free molecule of linear DNA (Kastoukoff et al. , 
1981) or as a circular molecule of DNA (Rock and Fraser, 1983). 
Alternatively, it may be molecularly rearranged or integrated into 
the cellular DNA (Puga et al. , 1984). However, Fenner et al. 
(1974) postulated that integration was unnecessary for latency to 
occur since neurones do not divide. Puga et al. (1978) suggested 
that latency occurred due to a block in transcription of the genome 
and it was later confirmed that limited transcription occurred
(Galloway et al., 1982).
In summary, HSV can persist in the neurones of its host.
There appears to be no expression of viral antigens during latency 
although a variety of stimuli can cause reactivation of the virus. 
Neutralising antibody is not necessary for the maintenance of 
latency although non-neutralising antibody and cell mediated 
immunity may be important. The entire viral genome is present in 
the host cell although its form is unknown, and only limited
transcription occurs.
The other major group of viruses known to persist in a silent 
non-productive form are the retroviruses. There are 3 subgroups of 
these viruses; the lentiviruses or slow viruses which include 
maedi-visna (MV) virus of sheep and equine infectious anaemia (EIA) 
virus; the oncoviruses which include FeLV, bovine leukaemia virus 
(BLV) and human T-lymphotropic virus type I (HTLV-I); and the 
spumaviruses, like feline syncytium-forming virus. The murine 
leukaemia viruses (MuLV) and avian leukosis virus also belong to 
the oncovirus subgroup of retroviruses and are more closely related
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to FeLV than the others. It is unknown if the murine and avian
viruses persist in their hosts in a latent form as does FeLV.
However, some work has been carried out in vitro on cell lines
infected with Gross MuLV (G-MuLV) and Friend MuLV (F-MuLV) and is
discussed below.
The pathogenesis of lentiviruses has recently been reviewed 
(Haase, 1986) but relatively little is known about the mechanisms 
by which these viruses persist in vivo. In culture, MV virus 
undergoes rapid replication and spreads throughout the culture 
resulting in cytolysis (Thormar, 1963). However, in vivo, the 
infection was non-lytic and the virus persisted in the lungs, 
central nervous system and haemopoietic system of the host (Brahic 
et al., 1981). The host develops neutralising antibodies which 
presumably prevent the dissemination of the virus through the body 
(Petursson et al., 1976). Haase et al. (1977) reported that the 
virus persisted in cells in a latent form and it was suggested that 
the production of infectious virus was blocked at the level of 
transcription (Brahic et al., 1981).
A major characteristic of MV virus is that it undergoes 
antigenic drift to produce variant viruses (Narayan et al. , 
1977a). The variant viruses arise due to point mutations in the
env gene (Scott et al., 1979; Clements et al., 1980) but do not
replace the original strain. Instead, it was found that 
accumulation of variant viruses occurred and that the host 
eventually made neutralising antibodies to each one (Clements and
Narayan, 1985). Since the original strain of virus remained in its
host, it was clear that antigenic drift was not essential for virus 
persistence (Petursson et al., 1985). Indeed, Thormar et al.
(1983) found that in longterm infections in vivo the appearance of 
antigenic variants was a rare event, although this did occur.
It was suggested that infected cells escaped immunosurveill- 
ance due to insufficient antigen production (Haase et al. , 1977). 
Neither humoral nor cellular immunity appeared to play a 
significant role in the maintenance of latency because immuno-
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suppression in the host did not lead to recrudescence of infection 
(Nathanson e t a l . , 1976; Narayan et al., 1977b).
Antigenic drift also occurs with EIA virus (Kono et al., 1973) 
and like MV virus the variants are due to point mutations on the 
env gene (Montelaro et al., 1984; Salinovich et al., 1986). 
However, EIA virus differs from MV virus as it undergoes cycles of 
replication and each new variant is refractory to the antibody 
which neutralised previous variants (Kono et al., 1973; Salinovich 
e t a l . , 1986). Another characteristic of EIA virus is that
non-neutralising antibody binds to the virus forming immune 
complexes which remain infectious. The virus is thus protected 
from neutralising antibody and therefore persists in the form of 
complexes (Mohanty and Dutta, 1981).
The molecular mechanisms by which the lentiviruses, in 
particular, MV virus, persist remain largely unknown and the role 
of antibody in their persistence is unclear.
The second subgroup of retroviruses, the oncoviruses, are 
perhaps a little more understood. As mentioned previously, it is 
not known if a latent state exists in animals exposed to the avian 
and murine viruses but in vitro studies on the maintenance of MuLV 
infections have been carried out.
Cells which were chronially infected with G-MuLV were killed 
in vitro by the presence of neutralising antibody plus complement. 
However, in the presence of antibody but in the absence of 
complement lysis did not occur, but antigenic modulation resulted 
(Ioachim and Sabbath, 1979) rather like the situation with measles 
virus. There was redistribution of both viral particles inside the 
cell as well as antigen expressed on the cell membrane. It has 
been reported that this antigenic modulation affected the degree of 
malignancy of infected cells (Ioachim et al., 1974; Ioachim, 1976) 
and such cells would escape the host's immune reponse. 
Antibody-induced antigenic modulation in vitro was reversible 
(Ioachim and Sabbath, 1979). The mechanisms by which antibody
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prevents the production of infectious virus is unknown. The 
binding of antibody to viral antigen expressed on the cell membrane 
may act as a signal to stop further antigen synthesis; it may 
decrease the rate at which antigen is produced or it may result in 
selective deletion of specific antigens.
The growth of F-MuLV-induced erythroleukaemia cells in vitro 
could be stopped by the addition of goat antiserum to the envelope 
glycoprotein, gp71 (Genovesi and Collins, 1983). As with G-MuLV it 
is believed that antigenic modulation occurs (Genovesi et al. , 
1977; Genovesi and Collins, 1983). This effect was found to be 
independent of complement and was demonstrated to be due to the 
presence of virus-specific IgG. Initially, specific modulation of 
gp71 occurred, followed by non-specific modulation of other viral 
antigens. These effects were reversible depending on the duration 
and concentration of antibody in the cultures (Genovesi and
Collins, 1983). For example, antigen re-expression occurred 
rapidly if antibody had been present for up to 48 hours, whereas 
the presence of antibody for 72 hours or longer resulted in a lag 
phase prior to the re-expression of viral antigens.
The mechanism by which this antibody has its effect is
believed to be due to its prevention of cells from entering the
G2 /M phase of the cell cycle. Antibody to the group or type 
specific determinants on the gp71 were capable of causing
cytostasis and the action of antibody binding to antigen was the 
critical factor (Genovesi and Collins, 1983).
Anti-gp71 antibody was used in vivo to protect mice from 
infection with F-MuLV. The antibody induced active humoral and 
cell mediated immune responses (Collins et al. , 1979; Genovesi et 
al., 1983) and it was suggested that such passive immunotherapy 
decreased the titre of infectious virus below the level necessary 
to induce immunosuppression and thus allowed the animal to mount 
an active immune response (Genovesi e t a l . , 1982).
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Antibody to the major envelope glycoprotein of MuLV therefore 
appears to have an inhibitory effect on viral expression in vitro 
and would appear to maintain the virus in a non-productive state. 
It would be of great interest to learn if such a .silent non­
productive state occurred in vivo, not only of MuLV, but also if 
avian leukosis virus.
Both HTLV-I and BLV which are closely related, cause latent 
infections in their hosts. HTLV-I is the aetiological agent of 
adult T-cell leukaemia (ATL). The viral genome is integrated in 
the DNA of the leukaemic T-cells of these patients (Yoshida et al., 
1984) although there is no expression of viral antigen in vivo 
(Miyoshi et al., 1982). However, when peripheral blood leukocytes 
from patients with ATL and from healthy carriers who have 
anti-HTLV-I antibodies were cultured there was spontaneous 
reactivation of virus and antigen expression occurred (Tochikura et 
al., 1985). After 3 days in culture approximately 2% of the cells 
contained antigen but virus gradually spread to 20% by 7 days and 
by 50 days all of the cells expressed antigen.
When these cells were cultured with anti-HTLV-I antibody from 
patients with ATL, healthy carriers or HTLV-I-positive monkeys, the 
reactivation of virus was inhibited. This effect was not permanent 
and was not due to cytotoxicity because re-expression of virus 
occurred even after the continuous presence of antibody for up to 
45-60 days. It was shown that it was antibody which exerted this 
inhibitory effect since pretreatment of the anti-HTLV-I serum with 
protein-A abolished the effect (Tochikura et al., 1985). However, 
MCAs to viral antigens were not used, so that it is not known with 
which epitope this human antibody reacted, although it is believed 
to be the viral envelope glycoprotein. The antibody was less 
effective in inhibiting reactivation if a proportion of the cells 
already contained antigen and it had no effect on cell lines which 
were continuously expressing virus. Tochikura et al. (1985) 
suggested that antigen expression both in vitro and in vivo was 
regulated by antibody and that the binding of antibody to genome- 
positive cells initiated a signal which inhibited expression.
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BLV causes enzootic bovine leukosis and persistent 
lymphocytosis. Like HTLV-I but unlike FeLV and MuLV, BLV infects 
only lymphocytes, and as in HTLV-I viral antigens are not expressed 
in vivo. However, complete infectious virus was detected as early 
as 3 hours after initiation of cultures of infected lymphocytes 
(Baliga and Ferrer, 1977; Kettmann et al., 1980). Gupta and Ferrer
(1982) showed that the expression of the major core protein, p25, 
could be inhibited by a non-immunoglobulin plasma protein in short­
term cultures of infected lymphocytes. This protein was present in 
the plasma of a majority of BLV-infected cattle but not in
uninfected cattle or cattle infected with other viruses and it was 
capable of preventing p25 expression even if cells already 
contained this antigen. When the protein was removed from the 
cultures, however, re-expression occurred (Gupta and Ferrer, 1982).
The protein also blocked the expression of p25 in BLV-infected 
fibroblast cell lines of both bovine and non-bovine origin but had 
no effect on cell lines infected with either FeLV or Rauscher- 
MuLV. It was therefore demonstrated that the protein was
BLV-specific (Gupta et al., 1984). It was found that the protein 
was in plasma of infected cattle but not in serum, it was not 
interferon and had a molecular weight of approximately 150,000. 
Using cloned BLV DNA in dot blot hybridisation Gupta et al. (1984)
claimed that the expression of the genome was blocked at the level
of transcription. These authors concluded that the inhibition of 
p25 expression was not caused by antibody. Attempts to inhibit 
expression of this antigen in cultured lymphocytes from 
BLV-infected cattle by mouse MCAs to a variety of BLV proteins, 
including the envelope glycoprotein, failed (A. Pacitti, 0. Jarrett 
and A. Burny, unpublished results).
Interestingly, Tsukiyama et al. (a; submitted for publication) 
discovered a platelet derived factor in the plasma of both 
BLV-infected and uninfected cattle which inhibited the effect of 
the protein described above, i.e. it reversed the inhibition of p25 
expression in cultured lymphocytes induced by the plasma protein. 
This effect was irreversible. This platelet derived factor
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increased p25 expression and was shown to be a mitogen to bovine 
lymphocytes and to both bovine and murine fibroblasts (Tsukiyama et 
al. b; submitted for publication). It appeared to have similar 
properties to platelet derived growth factor. It is unknown if the 
factor exerted its effect by stimulating the cell cycle or by 
stimulating viral transcription.
The mechanisms involved in the maintenance of latent HTLV-I
and BLV infections therefore remain controversial. The two viruses 
are very closely related and it is difficult to explain why 
antibody should play a role in the maintenance of latent HTLV-I
infection, at least in vitro, but not with BLV.
Latent FeLV infetions appear to be maintained by mechanisms 
similar to those which are involved in the persistence of the
paramyxoviruses and HTLV-I since anti-viral antibody inhibits the 
reactivation of virus in vitro. It has been shown by the use of 
MCAs to FeLV proteins that antibody to the neutralising epitope on 
the gp70 is necessary for this effect although the molecular
mechanisms involved remain to be established. It is possible that 
antigenic modulation occurs as in measles virus infection but if 
this were to occur expression of gp70 would be necessary. Attempts 
so far to demonstrate gp70 on latently infected cells have failed 
but the use of a more sensitive technique such as in situ 
hybridisation will perhaps clarify this matter. Other
immunological effector mechanisms may be involved such as 
complement dependence or cell mediated immunity as has been 
suggested for the control of latent HSV infection.
On the other hand, truly latent FeLV infections may not 
exist. Instead, what is regarded as latency may be a limited 
productive infection with release of amounts of virus in the blood 
below the levels of detection of the methods used in this study. 
Any virus released may be neutralised by antibody so that the 
production of infectious virus is limited to areas such as the bone 
marrow and epithelial cells. From the experiments described in 
Chapter 6 it was found that neutralising antibody appeared to
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prevent the spread of virus in vitro from bone marrow cells from a 
viraemic cat to those of an uninfected cat.
This phenomenon of limited viral production may be possible in 
vivo since, as described by Rojko et al. (1979a), virus enters the 
mouth and grows in the cells of the oropharynx and upper 
respiratory tract. Virus then infects circulating lymphocytes 
which are disseminated to the bone marrow and lymphatic tissues 
throughout the body. Subsequent spread to non-lymphoid tissues
occurs and virus can be found in myelomonocytic cells in the 
marrow, in circulating neutrophils and platelets, and finally in
epithelial cells in a variety of tissues. The host may
simultaneously develop an immune response which limits the 
infection to the bone marrow and the epithelia.
Indeed, cats with such infections have been reported. In the 
present study cat 4 was "latently" infected but produced infectious 
virus in her mammary glands, presumably in epithelial cells. 
Non-viraemic cats which have infectious virus in their saliva have 
been described (Jarrett et al., 1982; H. Lutz and 0. Jarrett, 
personal communication) and Lutz et al. (1980) isolated virus from 
the urine of a non-viraemic cat, although it is unknown if any of 
these cats had latent infections.
It is therefore not unreasonable to suspect that "latently
infected" cats actually produce infectious virus at extramedullary 
sites which would not be detected by the routine diagnostic 
techniques used in the field.
Such "latently infected" cats would complicate the control of 
the spread of FeLV and its eradication from multicat households by 
test-and-removal programmes and may be of particular importance in 
closed households such as breeding colonies. Cats like cat 4 
described in the present study, who produced virus in her milk and 
thus infected her kittens, may explain the reports of the 
reappearance of FeLV in households which were believed to have been 
freed of the virus. For these reasons it would be of interest to
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examine those cats which remained in these households for the 
presence of latent infections after this method of eradication had 
been used.
The continuation of the study of the control of latent FeLV 
infections will lead to a more complete understanding of other 
"latent" retroviral infections, including those which affect man 
such as HTLV-I. In addition, elucidation of the molecular 
mechanisms by which anti-gp70 antibody influences reactivation of 
latent FeLV infections should help us to understand how other 
persistent viral infections are maintained.
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